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1 Introduction 
The neurodegenerative diseases are defined by the European Commission as hereditary and 
sporadic conditions which are characterized by progressive nervous system dysfunction. They 
include diseases such as Alzheimer Disease (AD), Degenerative Nerve Diseases, Epilepsy, 
Stroke, Parkinson Disease, Multiple Sclerosis (MS), Huntington Disease and others. 
Alzheimer disease is here chosen to illustrate the impact of neurodegenerative diseases on the 
human society. The World Health Organization (WHO) revealed AD as the fourth highest 
source of overall disease burden in the high-income countries (WHO statistics, table 13). All 
these diseases have the degeneration of neuronal cells in common. In addition, injuries can 
also lead to neuronal deletions. The fact that the capacity for neural regeneration is limited in 
evolutionarily higher organisms including humans, leads to the requirement of replacement of 
nerve cells in humans. The replacement of neural cells by stem cells or induced pluripotent 
stem cells is highly discussed to be an emerging approach to treat neurodegenerative diseases 
(Steward et al., 2013).  
 
1.1 Stem cells 
Stem cells are defined by their ability to self-renew as well as their ability to differentiate into 
multiple cell types (Zhu et al., 2013), and therefore can serve as a source for cell replacement 
of damaged neurons. Stem cells are able to self-renew by symmetric division and differentiate 
by asymmetric cell divisions (Martin-Rendon and Watt, 2003). Stem cells are classified by 
their potency to develop into other cell types, as totipotent, pluripotent, and multipotent. 
Totipotent stem cells have the ability to differentiate into every cell type of an organism and 
are resulting out of a fertilized ovum (zygote) and their daughter cells up to the fourth cell 
division. Pluripotent cells, for example embryonic stem cells (ESC), have the ability to give 
rise to all three germ layers: mesoderm, ectoderm and endoderm (Loebel et al., 2003). 
Multipotent stem cells are cells which are restricted to differentiate into cell types depending 
on their cell source (Korbing and Estrov 2003).  
Traditionally, as a source of neural stem cells for replacement purposes, have served adult 
stem cells isolated from the hippocampus and subventricular zone (Steward et al., 2013). But 
due to the low amount of adult stem cells it was needed to establish other stem cell sources, 
including human embryonic stem cells (hESCs) and human induced pluripotent stem cells 
(hiPSCs). Especially the method of hiPSC generation is a great breakthrough to improve the 
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production of mature neuronal cell types from a patient-specific somatic cell source and, 
therefore, negate the ethical and immune-rejection concerns. 
 
1.1.1 Neural Progenitor Cells 
Neural stem cells can divide into neural progenitor cells (NPCs) which are more restricted in 
their differentiation potential and can be found in the hypothalamus, the dentate gyrus of the 
hippocampus, the forebrain, the subventricular zone, and the subgranular zone of the dentate 
gyrus (Temple and Alvarez-Byulla, 1999). They derive out of the neural tube which forms the 
central nervous system and differentiate due to mesodermal initiated signaling (Kandel et al., 
2000). NPCs have the ability to differentiate into neurons which are classified by the 
expression of the neuronal specific β-tubulin Tuj1 (also known as class III β-tubulin) which is 
able to heterodimerize with α-tubulins to form microtubules, which are essential components 
of the cytoskeleton. In addition, differentiating NPCs express HuC/D. Hu proteins are RNA-
binding proteins who stabilize specific target mRNAs (Perrone-Bizzozero and Bird 2013). 
Furthermore, they can differentiate into glial cells, like the myelinating oligodendrocytes 
which express the surface antigene O4 and into astrocytes, which are positive for the calcium 
binding protein S100β (Perrone-Bizzozero and Bird 2013).  
Differentiation of NPCs is controlled by a multitude of different pathways, which regulate the 
neurogenesis as well as gliogenesis. Understanding these mechanisms will definitely provide 
the basis for directing differentiation of human NPCs for clinical applications. 
 
1.1.1.1 ReNcell VM cells 
Most of the knowledge how NPCs differentiate is based on murine models. Therefore, the 
cells of choice for identifying the pathways underlying neuronal differentiation are human 
neuronal progenitor cells, like the ReNcell VM cells, which have defining properties: self-
renewal, human origin, multipotency, fast growth, virtually unlimited availability, and they 
are suitable for molecular manipulation. These cells have the ability to differentiate into 
multiple neuronal cell types and make them attractive as powerful tools in research. ReNcell 
VM cells are a v-myc retrovirally immortalized human cell line and were derived from the 
ventral midbrain of a 10-week old male fetus (Donato et al., 2007). Recent studies have 
shown that v-myc induction can enhance the self-renewal of neural progenitors derived from 
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fetal human brain with no tumorigenic potential either in vitro or in vivo and creates 
karyotypically stable cell lines (Kim et al., 2012). This cell line is able to differentiate after 3 
days into HuC/D and Tuj1 positive neurons (Morgan et al., 2009; Hübner et al., 2010; 
Schmöle et al., 2010). Furthermore, proliferating cells express the neuronal marker Nestin 
(Donato et al., 2007) - an intermediate filament expressed in many neural precursor cells 
(Lendahl et al., 1990) - and SOX2 (SRY-related HMG-box gene 2; Donato et al., 2007) which 
is a known transcription factor expressed in neural precursor/stem cells (Episkopou 2005; 
Jiang et al., 2008). For phase contrast pictures see appendix 7.1. 
 
1.1.1.2 Induced pluripotent stem cell derived neural precursor cells (iPS-NPCs) 
By reprogramming somatic cells into pluripotent state using defined transcription factors, 
Yamanaka´s group provided a new basis for cell replacement therapy using stem cells 
(Takahashi and Yamanaka, 2006). This method enabled the generation of induced pluripotent 
stem cells with abilities comparable to that of embryonic stem cells, but without the ethical 
and immune-rejection concerns. Therefore, the iPSCs are widely used for patient-specific 
analyzes of different diseases (Ito et al., 2012). Moreover, recently a substantial function of 
them in pre-clinical models of ischemic brain injury has been revealed (Zhu et al., 2013). 
The here used iPS-NPCs were derived via dual SMAD inhibition by using the human iPS cell 
line hFib2-iPS5 (Park et al., 2008; Trilck et al., 2013). Cells are positive for the stem cell 
markers Nestin and SOX2, like ReNcell VM cells. In addition, they are able to differentiate 
into HuC/D positive cells after 18 days of growth factor removal. For phase contrast pictures 
see appendix 7.2. 
 
1.2 Regulation of the neuronal differentiation  
The neural induction starts with the development of the neural plate out of the ectoderm of the 
blastocyst, which afterwards forms the neural tube. Out of the front part of the neural tube the 
forebrain and midbrain arise while the hindbrain and the spinal cord resulting out of the back 
part of the neural tube. Differentiation is initiated by defined temporal sequences from the 
mesoderm (Kandel et al., 2000). These temporal sequences are widely conserved in vertebrate 
species (Bayer and Altmann, 1991). Diverse studies have revealed numerous signaling 
pathways that control the temporal sequences and discovered that the effects on neuronal 
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progenitor cells are highly dynamic, depending on the stage of development and the local 
niche (Denham et al., 2009). The main pathways which are regulating the differentiat ion and 
analyzed in this work are the Wnt signaling pathway, the Notch pathway, the BMP pathway 
and the JAK/STAT3 pathway. All of these pathways regulate target genes, representing 
different basic helix-loop-helix (bHLH) transcription factors. These factors form hetero 
dimers with ubiquitously expressed bHLH E proteins, such as E12 and E47, through their 
HLH domain. Hetero dimers bind to DNA through their basic domain and activate the 
transcription of genes that have E boxes in their promoter region (Hsieh, 2012).  
 
1.2.1 The Wnt pathways 
The Wnt signaling pathway plays an important role in the development of the central nervous 
system. Wnts are required for early patterning by acting as posteriorising signal, for the 
development of neural progenitor cells, cell proliferation, for cell fate determination, and stem 
cell renewal (Ciani and Salinas, 2005). Furthermore, the Wnt signaling pathway is 
substantially involved in neuronal polarization (Habib et al., 2013), neuronal migration, axon 
guidance, dendrite development, and synapse formation (Inestrosa and Arenas, 2010). 
Strikingly, the effect of Wnt is strongly depended on time and vicinity, for example it can 
either induce or repress the growth of human breast cancers depending on molecular pathways 
which are expressed in the affected cells (Green et al., 2013). 
The Wnt pathway is named for its ligands and was discovered more than 30 years ago. 
Sharma and Chopra described in 1976 Drosophila melanogaster mutants that exposed 
reduced or absent wings and named this gene wingless (wg) (Sharma and Chopra 1976). 
Later, in 1984 Nusse and Varmus identified the gene int-1, short for integration 1, which 
induced mouse mammary tumors, which revealed to be a homolog of wg (Nusse et al., 1984). 
The names were merged into the today well known Wnt. The Wnt ligands are secreted 
glycoproteins with 19 known family members which are highly conserved among animal 
species (van Amerongen and Nusse, 2009). Many Wnt proteins are posttranslational modified 
by glycosylation and palmitoylation as shown for Wnt-3a (Willert et al., 2003, Takada et al., 
2006).  
A variety of different Wnt signaling pathways is known and on the basis of early studies, they 
have been classified as either canonical (β‑catenin dependent) or non-canonical  
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(β‑catenin independent). However, this classification is not appropriate, due to the fact that 
various cross talks are known in different cellular contexts (Niehrs, 2012).  
The best described pathway is the β-catenin dependent pathway afterwards follows the  
β-catenin independent pathways; the PCP (planar cell polarity) pathway and the Ca2+ 
pathway. But there are more than 15 different Wnt-receptors and co-receptors, and the 
specific combination of these together with 19 different Wnt ligands determines the 
downstream pathway and the effect on the cell, whereas the main part seems to depend on the 
co-receptor (Figure 1; Niehrs, 2012).  
 
 
Figure 1: Overview of major Wnt pathways, receptors and co-receptors. PCP= planar cell polarity, LRP= 
LDL receptor-related proteins, ROR= receptor orphan, RYK= transmembrane receptor tyrosine kinase, MUSK= 
muscle-specific receptor kinase, PRK7= Tyrosine-protein kinase-like 7 .Diagram from Niehrs, 2012. 
 
Wnt ligands can activate more than one pathway at the same time. For example, Wnt-3a can 
activate both, the β-catenin dependent pathway and the Ca2+ pathway in human articular 
chondrocytes, with distinct transcriptional targets (Nalesso et al., 2011).  
In addition, the Wnt pathways are known to interact with a variety of different other 
pathways. The glycogen synthase kinase 3 (GSK3) for example has potentially 20 % of all 
proteins in a cell as substrates and can therefore likely affect plenty of other signaling 
pathways (Taelmann et al., 2010).  
 
1.2.1.1 The β-catenin dependent pathway 
When the β-catenin dependent pathway is not activated, β-catenin is targeted for ubiquitin-
mediated proteasome degradation of the E3 ubiquitin ligase complex (Figure 2, A). This 
targeting is performed by the β-catenin destruction complex, consisting of the scaffold 
proteins axin inhibition protein (AXIN), adenomatous-polyposis-coli (APC), GSK3, and 
casein kinase 1α (CK1α). In the active state, this destruction complex is inhibited (Figure 2, 
B). This leads to an increase of active β-catenin in the cytosol and its translocation into the 
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nucleus, where it triggers the transcription of Wnt target genes by association with the 
transcription factor T cell factor/lymphoid enhancing factor (TCF/LEF; Gordon and Nusse, 
2006).  
 
 
Figure 2: Simplified scheme of the β-catenin dependent Wnt pathway. A: Glycogen synthase kinase 3 
(GSK3) phosphorylates β‑catenin, which triggers its degradation. B: In the presence of Wnt ligand, the 
destruction complex (comprising GSK3, CK1α, AXIN and APC) is recruited to the Wnt–receptor complex and 
inactivated. This allows β‑catenin to accumulate and translocate to the nucleus, where it activates the 
transcription of target genes under the control of T cell factor (TCF), among others. Modified diagram from 
Niehrs, 2012. 
 
In detail, Wnt ligands bind to members of the Frizzled (Fz) family of seven transmembrane 
domain receptors, which are G-protein-coupled receptors (Koval et al., 2011). In addition, 
Wnts bind to the single-pass transmembrane co-receptors LDL receptor-related proteins 5 and 
6 (LRP5/6; He et al., 2004), which results in the phosphorylation of LRP5/6, the activation of 
cytoplasmatic protein Dishevelled (Dvl) and the production of phosphatidylinositol (4,5)-
bisphosphate (PIP2; Pan et al., 2008). Increased PIP2 induces oligomerization and clustering 
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of LRP5/6, furthermore, it forms a signalosome which recruits AXIN and Axin-bound GSK3 
complexes to the cell surface (Zeng et al., 2008 and Tanneberger et al., 2011). This, and the 
fact that AXIN is the scaffold protein that directly binds to many of the involved components 
and brings them within close proximity to each other, makes it to the limiting component of 
the β-catenin destruction complex (Lee et al., 2003). Furthermore, clathrin and adaptor 
protein 2 (AP2) are required for the formation of LRP6 signalosomes (Kim et al., 2013). 
Taelman et al., 2010 clearly showed a sequestration of the Wnt induced receptor signaling 
complex, the signalosom, into multivesicular bodies (MVBs) which are positive for the 
lysosomal marker Rap7. In addition, they found that GSK3 is sequestered into the lumen of 
these MVBs, thus blocking its ability to affect its target substrates in the cytoplasm such as β-
catenin (Figure 3). 
The phosphorylated cytoplasmic domain of LRP6 is able to bind and therefore inhibit the 
GSK3. This inhibition of the GSK3 activity leads to blocking of the β-catenin 
phosphorylation which is now able to translocate into the nucleus and bind to the TCF/LEF. 
TCF binds to the Wnt-responsive element [CCTTTGWW (W can be either T or A)] and starts 
the expression of the Wnt target genes like AXIN2 (Wu et al., 2009, Hatzis et al., 2008). In 
addition, there is a verity of studies showing that diverse DNA-binding transcription factors 
(e.g. SMAD3) bind to β-catenin to activate or repress β-catenin dependent Wnt target genes. 
Due to the large number of TCF binding sites and numerous transcriptional co-regulators, it is 
clear that the gene expression may induce dramatic changes in the cell (Cadigan, 2012). In 
ReNcell VM cells, for example, the treatment of Wnt-3a leads to an induction of AXIN2 
(Hübner et al., 2010). 
In addition, β-catenin is a constitutively expressed protein connecting cadherin cell adhesion 
molecules to the cytoskeleton (Aberle et al., 1996). Furthermore, there are evidences which 
support potential influence of cadherins on Wnt signaling. Some studies demonstrating that 
proteolytic cleavage of cadherins by proteases such as ADAM10 and presenilin-1  
(γ-secretase) is able to release β-catenin and therefore activates transcription of β-catenin 
dependent Wnt target genes (Reiss et al., 2005, Uemura et al., 2006).  
There are plenty of substances which are able to inhibit the β-catenin dependent Wnt 
pathway. One of the best described is Dickkopf-1 (Dkk-1) which binds the co-receptor 
LRP5/6 and blocks its interaction with Wnt ligands (Semenov et al. 2001; Mao et al. 2002). 
Recently, X-ray crystal structure analysis revealed that the extracellular region of LRP6 binds 
to the C-terminal domain of Dkk1 (Ahn et al. 2011; Cheng et al. 2011). In addition, secreted 
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Fz-related proteins (sFRPs) are able to bind and sequester Wnt ligands to block their 
association with Wnt-receptors (Bovolenta et al., 2008). Another way to modulate the β-
catenin dependent Wnt pathway is to inhibit GSK3 with a small molecule named SB216763 
which was extensively analyzed in our work group (Schmöle et al., 2010). 
 
 
 
Figure 3: Scheme of the β-catenin dependent Wnt signaling through the sequestration of GSK3 inside 
MVBs. Binding of GSK3 to the Wnt-receptor complex sequestrates GSK3 inside small intraluminal MVB 
vesicles, causing its cytosolic substrates such as β-catenin and many other proteins to become stabilized. The 
initial GSK3 molecules are recruited to the receptor complex bound to Axin, ensuring that the GSK3 fraction 
bound to the destruction complex is depleted first. Diagram from Taelman et al., 2010. 
 
1.2.1.2 The β-catenin independent pathways 
The β-catenin independent pathways are named due to their independency of β-catenin. The 
best described pathways are the PCP pathway and the Ca
2+
 pathway. In addition, an 
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increasing number of other pathways are starting to emerge which are named after the specific 
combination of essential receptor and ligand (e.g. Wnt-5a-ROR-, RYK-Wnt-, PTK7-Wnt- 
pathways etc.). Increasing evidences suggesting that in vertebrates the PCP and Wnt-5a–ROR 
signaling pathways substantially overlap (Ho et al., 2012). 
 
The PCP pathway 
The PCP pathway is essential for the organization of multicellular structures and tissue 
remodeling as well as the control of polarized cell migration and coordinated cell movements. 
The Wnt ligand binds to a combination of Frizzeld and a co-receptor (e.g. ROR or RYK) 
which leads to an activation of Ras-related C3 botulinum toxin substrate 1 (RAC1) and 
subsequently of JUN-N-terminal kinase (JNK) which starts the transcription of the PCP target 
genes (Figure 4). Furthermore, the small GTPase Ras homologous A (RHOA) is activated 
through activated Dishevelled associated activator of morphogenesis (DAAM), which in turn 
activate RHO kinase (ROCK) and therefore modulates actin polymerization (Nomachi et al., 
2008, Schlessinger et al., 2009). While the RYK dependent PCP signaling can activate the β-
catenin dependent signaling (Berndt et al., 2011), the ROR2 dependent signaling inhibits the  
β-catenin dependent pathway (Winkel et al., 2008). The list of additionally factors which 
cooperate with the core PCP genes is continually expanding (Dworkin et al., 2011). 
Furthermore, the γ-secretase can cleave the RYK receptor and induce the target genes of the 
RYK-Wnt pathway (Lyu et al., 2008).  
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Figure 4: Scheme of the planar cell polarity (PCP) pathway. PCP signaling triggers activation of the small 
GTPases RHOA and RAC1, which in turn activate RHO kinase (ROCK) and JUN-N-terminal kinase (JNK), 
respectively, leading to actin polymerization and microtubule stabilization. Diagram from Niehrs, 2012. 
 
The Ca
2+
 dependent pathway 
The second β‑catenin independent pathway that has been described is the Wnt-Ca2+ pathway. 
Here, the Wnt ligands bind to Frizzled and defined co-receptors (Figure 1) which activate 
phospholipase C (PLC). Subsequently, this activation leads to a short-lived increase of the 
intracellular signaling molecules inositol 1,4,5-triphosphate (IP3), 1,2 diacylglycerol (DAG), 
and Ca
2+
 (Figure 5). This elevation of secondary messengers - which are derived from 
membrane-bound phospholipid phosphatidyl inositol 4,5-bisphosphate (PPIP) - promotes the 
release of calcium ions from the endoplasmatic reticulum (ER). The Ca
2+
 release activates 
calmodulin-dependent kinase II (CAMKII), Calcineurin and protein kinase C (PKC; Kühl et 
al., 2000). CAMKII and PKC are able to inhibit the β-catenin dependent pathway (De et al., 
2011). PKC activates CDC42 subsequently induce actin polymerization. In contrast the 
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activation of Calcineurin by Ca
2+ 
induced the transcriptional regulator nuclear factor 
associated with T cells (NFAT) and its target genes (Saneyoshi et al., 2002). 
 
 
Figure 5: The Wnt- Ca
2+
 pathway. Wnt binding to Frizzeld and co-receptors activates Ca2+- and Calmodulin-
dependent kinase II (CAMKII), protein kinase C (PKC) and Calcineurin. Calcineurin activates nuclear factor of 
activated T cells (NFAT), which regulates the transcription of genes controlling cell fate and cell migration. The 
Ca2+ pathway inhibits β‑catenin signaling. Diagram from Niehrs, 2012. 
 
1.2.2 The Notch pathway 
The Notch signaling pathway is well known as an important signaling mechanism for 
communication between neighboring cells which is essential for specification of neuronal 
identity, division, survival and migration. This pathway plays a major role in the process of 
the lateral inhibition which regulates the differentiation of an initially homogenous cell 
population into distinct cell types (Kopan et al., 2009, Kageyama et al., 2009). Furthermore, 
the Notch pathway is associated with human diseases such as cerebral autosomal dominant 
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arteriopathy, subcortical infarcts and leukoencephalopathy (CADASIL) and certain cancers 
(Louvi et al., 2012). 
In the Notch signaling pathway are usually two cells involved. One cell expresses the Notch 
ligands Delta-like (Dll1, 3, and 4) and/or Jagged (JAG1 and JAG2) while the second cell 
expresses at least one of the four receptors (Notch1–4). The Notch receptor has three cleavage 
sites (S1, S2, S3). The first cleavage (S1) occurs during maturation and trafficking to the cell 
surface membrane which converts the notch polypeptide into a heterodimer, composed of the 
notch extracellular domain (NECD), the transmembrane fragment (N
TM
) and the intracellular 
domain (NICD). This Notch receptor is now, upon Dll1 activation, cleaved by ADAM-family 
metalloproteases at site 2 (S2) which releases NECD. Finally, Notch is cleaved by presenilin 
proteases of the γ-secretase complex progressively from site 3 (S3) to site 4 (S4; Fortini et al., 
2009). The cleaved intracellular domain of the notch receptor (NICD) is released from the cell 
membrane and translocates to the nucleus, where it associates with the DNA binding protein 
RBP-Jκ (Figure 6). The transcriptional coactivator Mastermind (MAM) then recognizes the 
NICD/RBPjκ interface, and this triprotein complex recruits additional coactivators (Co-A) to 
activate the transcription of Notch target genes. In the absence of NICD, RBP-J may associate 
with ubiquitous corepressor (Co-R) proteins and histone deacetylases (HDACs) to repress 
transcription of some target genes (Kopan et al., 2009, Imayoshi et al., 2013).  
The best described target genes of the Notch pathway are the HES and related HEY genes 
which encode a family of basic helix–loop–helix (bHLH) transcriptional repressors. They 
inhibit the transcription of their target genes, such as MASH1 (ASCL1) and Neurogenins by 
directly binding to the specific promotor or by dominant negative function on E protein 
availability, thereby preventing undifferentiated precursor cells from achieving differentiated 
phenotypes (Kageyama et al., 1997). Among the target genes, HES5 expression has been 
shown to be mostly dependent on notch signaling. Other notch target genes, including HES1, 
HES3, and HES7, are also regulated by signaling pathways other than notch signaling 
(Androutsellis-Theotokis et al., 200; Wall et al., 2009; Niwa et al., 2007). Moreover, the 
target genes expression oscillates in various cell types, such as fibroblasts, NSCs, and 
embryonic stem cells (Kageyama et al., 2009). In somitogenesis, they are periodically 
expressed in a wave-like fashion initiating at the posterior end and moving towards the 
anterior region of the presomitic mesoderm (PSM), where every wave leads to the generation 
of a pair of somites (Kageyama et al., 2012).  
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Figure 6: Scheme of the Notch signaling pathway. The Notch receptor is activated by binding to a ligand 
presented by a neighboring cell. A conformational change, then, exposes site 2 (S2) in Notch for cleavage by 
ADAM metalloproteases. γ-secretase then cleaves the Notch transmembrane domain progressively from site 3 
(S3) to site 4 (S4) to release the Notch intracellular domain (NICD). Subsequently, NICD enters the nucleus 
where it associates with the DNA-binding protein RBP-Jκ and starts the transcription of the target genes. 
Diagram from Guo et al., 2011.  
 
The main point in Notch activation is the release of the Notch intracellular domain by cutting 
the Notch receptor with a γ-secretase. To inhibit γ-secretase activity the small molecule 
DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester) is widely 
used (Ong et al., 2006, Nelson et al., 2006). But it inhibits not only the release of the Notch 
intracellular domain but also affects other γ-secretases, which can lead to multifarious 
ramifications (Bay and Pfaff, 2011). Another approach to inhibit the Notch signaling pathway 
is the downregulation of the co-transcription factor MAM. In contrast, the transcription factor 
RBP-J is difficult to efficiently downregulate due to its long protein half-life (Kopan et al., 
2009). 
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1.2.3 The BMP pathway 
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β 
(TGF-β) superfamily (Miyazono et al., 2010). BMPs were originally described as factors that 
induce bone formation (Urist, 1965). Meanwhile, they were described to play a role in various 
cell types and tissues and controlling embryogenesis and the formation and maintenance of 
the nervous system including dendritic and axonal growth, synapse formation and 
stabilization etc. (Mehler et al., 1997, Chen et al., 2004).  
The BMPs are with 33 members the largest subfamily of the TGF-β superfamily. They are 
able to signal through a canonical SMAD dependent pathway (TGF-β/BMP ligands, receptors 
and SMADs) and a non-canonical SMAD independent pathway (e.g. mitogen-activated 
protein kinase pathway p38, MAPK p38). The specific ligand-receptor combinations to 
activate these non-canonical pathways and specific signaling outcomes are still in discussion 
and need to be studied. 
In the canonical pathway, the BMPs bind to a heterotetrameric complex of transmembrane 
receptors known as type I and II serine/threonine kinase receptors (Mueller et al., 2012). A 
ligand-receptor specific combination of interaction is still in discussion and seems to be cell 
type dependent (Hinck, 2012). The activation of type I receptors leads to a phosphorylation of 
receptor regulated (R)-SMADs (SMAD1, 2, 3, 5, and 8) which induce the formation of a 
multimeric complex composed out of R-SMADs and SMAD4 that translocate into the nucleus 
where it starts the transcription of BMP target genes (Figure 7; Feng et al., 2005, Hill, 2009). 
The main target genes of the BMP pathway are the inhibitor of differentiation 1 and 3 (ID1 
and ID3) which are HLH transcription factors. They lack the basic region which makes them 
unable to bind to DNA but dimerization of IDs with other bHLH leads to an inhibition of the 
DNA binding ability of the bHLH transcription factors (Norton, 2000). Moreover, IDs not 
only inhibit transcriptional function but also promote the degradation of neurogenic bHLH by 
sequestering ubiquitous E proteins (Vinals et al., 2004). Takizawa et al. (2003) described that 
ID and HES play a major role in the negative effects of BMPs on differentiation of neuronal 
precursors.  
There are several known molecules which are able to inhibit the BMP pathway. The most 
frequent used is Noggin which binds to the BMP ligand and therefore impairs the binding to 
the receptor and inhibits the SMAD1, 5, 8, and MAPK p38 (Yu et al., 2008). The compound 
C (Dorsomorphin) is a potent inhibitor of AMP-activated protein kinase (AMPK) and inhibits 
BMP4 induced signaling and does not affect MAPK p38 (Yu et al., 2008). The small 
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molecule SB431542 inhibits ALK1 as well as ALK7 and therefore SMAD2 and 3 (Inman and 
Hill, 2002). In addition, the inhibitory SMADs, SMAD6 and SMAD7, block BMP signaling 
by preventing phosphorylation of R-SMADs by binding to active receptor complexes 
(Derynck and Zhang, 2003). Another known mechanism is the degradation of SMADs 
through the ubiquitin proteasome pathway or by mitogen-activated protein (MAP) kinase and 
GSK3 phosphorylation (Wicks et al., 2006, Fuentealba et al., 2007).  
 
 
Figure 7: Simplified scheme of the BMP pathway. BMP ligands bind to the BMP receptors BMPR1 and 
BMPR2. Phosphorylated BMPR1 subsequently phosphorylates SMAD1, SMAD5 and SMAD8, which associate 
with SMAD4 and enter the nucleus, where they regulate gene expression. The BMP signal can be blocked by 
extracellular antagonists, such as Noggin, which bind BMP ligands and prevent their association with the BMP 
receptors. Diagram from Hardwick et al., 2008. 
 
Moreover, BMPs were described to promote astrocytic differentiation together with leukemia 
inhibitory factor (LIF) by activating astrocyte specific promotors through a STAT3-
p300/CBP-SMAD1 complex (Nakashima et al., 1999). Scholl et al. (2012) revealed that the 
ability of BMPs and STAT3 to promote astrogliogenesis dependends on the histone 
acetylation/deacetylation machinery. This machinery regulates the chromatin structure and 
therefore is essential for the regulation of gene transcription. Chromatin is dynamically 
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regulated through a variety of mechanisms and enzymes including the histone 
acetyltransferases (HAT) and deacetylases (HADAC). This will finally lead to an open or 
closed nucleosomal DNA structure and therefore enables transcription factors to bind to 
promotors and regulate transcription. The inhibiton of HDAC by TSA (Trichostatin A) leads 
to an increase of STAT3 levels (Scholl et al., 2012), which in turn regulates together with 
BMP the astrogliogenesis (Nakashima et al., 1999). 
In addition, the BMP pathwaywas described to affect plenty of different other pathways and 
proteins, for example HES5 (Nakashima et al., 2001) and SMAD was discovered to interact 
with Dvl-1 in mouse MSCs (Liu et al., 2006). Moreover, Masserdotti et al. (2010) revealed 
that the zinc-finger protein ZFP423 triggers a cooperative interaction between NICD and the 
SMAD complex, which leads to a strong activation of HES5. Finally, AXIN can facilitate 
TGF-β signaling by presenting SMAD3 to the type I TGF-β receptor (Furuhashi et al., 2001). 
 
1.2.4 The JAK/STAT3 pathway 
Signal transducer and activator of transcription 3 (STAT3) belongs to a family of seven 
transcription factors which are able to modulate a variety of biological processes like cell 
growth, inflammation, embryological development, and axonal regeneration in the spinal cord 
(Qiu et al., 2005).  
STAT3 is activated in response to growth factors, cytokines, and hormones. Binding of these 
ligands to the epidermal growth factor receptor (EGFR) activates Janus kinase (JAK), which 
phosphorylates STAT3 at tyrosine 705 (Figure 8). This phosphorylation leads to a 
dimerization and translocation of STAT3 into the nucleus where the dimer is able to trigger 
STAT3 target genes Bcl-xL, cyclin D1, c-myc, Twist and Survivin (Dziennis and Alkayed, 
2008). Another mechanism of STAT3 activation is the phosphorylation by non-receptor 
tyrosine kinases such as SRC and activation by G-protein coupled receptors (Ram and 
Iyengar, 2001). The STAT3 signaling can be inhibited through an inhibition of JAK e.g. the 
substance JAK-Inhibitor 1 which inhibits the phosphorylation of STAT3 by JAK (Pedranzini 
et al., 2006). In contrast, the activation and translocation of STAT3 can be activated with the 
small molecule 5-aminoimidazole-4-carboxamide-1-D-ri-bofuranoside (AICAR; Zang et al., 
2008). 
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Figure 8: Scheme of the JAK/STAT3 pathway. STAT3 is activated downstream of receptor tyrosine kinases 
(e.g., EGFR), cytokine receptors via associated Janus family kinases (JAKs). Transcriptional induction of 
cytokines and EGF ligands can lead to autocrine stimulation and sustained STAT3 phosphorylation. After 
phosphorylation, STAT3 dimerizes and translocates to the nucleus, where STAT3 dimers directly regulate gene 
expression of transcriptional targets including Bcl-xL, cyclin D1, c-myc, Twist and Survivin. Diagram from 
Macias et al., 2013 
 
1.3 Aim of the study 
Hübner et al. (2010) demonstrated the induction of the β-catenin dependent Wnt pathway by 
treatment of Wnt-3a and transfection with Wnt-3a as well as stabilized β-catenin 
overexpression plasmid in the human neural progenitor cell line (ReNcell VM). However, 
only Wnt-3a but not overexpression of stabilized β-catenin led to an increase of neuronal 
differentiation as judged by HuC/D and Tuj1 positive cells. In addition, pharmacological 
inhibition of Notch signaling in these cells resulted in increased neuronal differentiation 
suggesting an important role for the Notch pathway in controlling neuronal differentiation. 
Moreover, further studies revealed that Wnt-3a, in contrast to stabilized β-catenin, was able to 
modulate Notch target genes HES1/HES5 and GFAP in ReNcell VM cells (Rayk Hübner, 
personal communication). These data pointed out a mechanism by which Wnt-3a 
independently of β-catenin increases neuronal differentiation, which may be based on Notch 
target gene modulation. 
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Therefore the aim of this study was at first to verify the active Notch pathway in 
differentiating ReNcell VM cells by pharmacological inhibition with DAPT. The 
differentiating cells should be treated with DAPT and analyzed via FACS to detect the 
amount of cells positive for the glial marker GFAP, S100β and neuronal marker Tuj1 and 
HuC/D, and by qRT-PCR to analyze the mRNA levels of the Notch target genes HES1 and 
HES5 as well as the neurogenic MASH1 and the glial marker GFAP. This will, in addition, 
reveal the importance of the Notch pathway in the differentiation of ReNcell VM cells. The 
detection of the mRNA levels will be useful due to the fact that there are no post-translational 
modifications known which would regulate these genes independent of their mRNA levels. In 
contrast, the activation of the Notch pathway by overexpression of the Notch intracellular 
domain 1 (NICD1) should prove through a rescue experiment the Notch dependency of DAPT 
and simultaneously emphasize the importance of Notch in the differentiation of human neural 
progenitor cells.  
The second step is to verify the effect of Wnt-3a on Notch target genes HES1 and HES5 by 
treatment of ReNcell VM cells with recombinant Wnt-3a and to extend the analysis by 
detecting the mRNA levels of MASH1 and GFAP. Furthermore, the effect of Wnt-3a on the 
amount of the cells for the marker Tuj1, HuC/D, S100β and GFAP should be measured via 
FACS. Due to the fact that Wnt-3a as well as DAPT are able to reduce HES5 and affect the 
differentiation of neural progenitor cells, it will be analyzed if this effect is additive. In 
addition, the time dependency of this effect should be further evaluated by analyzing time 
points between 1 and 72 hours of differentiation and by determining the time frame where 
progenitor cell differentiation can be modulated by Wnt-3a and other substances.  
Because we found Wnt-3a to regulate HES genes independent of β-catenin it was the aim of 
this study to reveal the underlying mechanism. Therefore, it should be investigated if 
upstream proteins of the β-catenin dependent pathway are involved in the Wnt-3a effect. 
Single components of the Wnt pathway should be inhibited through specific inhibitors to 
analyze their impact in the differentiation. SB216763 should be used to inhibit GSK3, Dkk-1 
to inhibit Wnt-3a - LRP5/6 interactions and sFRP1 to impair the connection between Frizzled 
and Wnt. The inhibition of these interactions will reveal if they are essential for the effect of 
Wnt-3a. In addition, the dependency of the Wnt-3a effect on single Notch pathway 
components should be determined by overexpression of NICD1, HES1 and HES5 in order to 
reveal their importance for the Wnt-3a effect and for the differentiation of ReNcell VM cells.  
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Moreover, other pathways should be analyzed which potentially might link Wnt-3a and the 
modulation of Notch target genes. It was, for example, hypothesized that Wnt-3a may act via 
inhibition of BMP. To assess that possibility, it should be analyzed whether inhibition of this 
pathway using Noggin, Dorsomorphin and SB431542 is able to mimic the Wnt-3a effect. 
Since SMAD1 is known to modulate together with STAT3 the level of GFAP (Nakashima et 
al., 1999), on this account, a potential modulation of the STAT3 activity should be assessed 
via western blot analysis. For analysis of the JAK/STAT3 pathway in ReNcell VM cells the 
pSTAT3 activator AICAR and inhibitor Jak-Inhibitor-1 should be investigated. If an active 
JAK/STAT3 pathway is detectable, nuclear pSTAT3 in Wnt-3a and DAPT treated cells 
should be quantified. 
Moreover, to rule out the possibility that the observed Notch modulations and the effect on 
neuronal differentiation are not strictly a cell-type specific phenomenon a second, neural cell 
system based on iPS cells should be utilized. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Technical equipment 
Table 1: Technical equipment 
Type Name Supplier 
agarose gel chamber Mini-SubII Bio-Rad 
balance MCBA 100 Sartorius 
cell counter CASY Innovatis 
cell culture microscope Eclipse TS100 Nikon 
centrifuge Z383K Hermle 
centrifuge Z233MK-2 Hermle 
centrifuge Universal 30 RF Hettich 
centrifuge Microfuge 16 Beckman Coulter 
centrifuge Avanti J-25 Beckman Coulter 
FACS FACSCalibur Becton Dickenson 
fluorescence microscope Biozero Keyence 
fluorescence microscope Eclipse TS200 Nikon 
gel documentation camera C-5050 Olympus 
gel documentation system TransilluminatorBioview biostep 
heating block Thermomixer eppendorf 
incubator WTC Binder 
incubator T6 Heraeus 
nucleofector NucleofectorII Amaxa 
PCR-Cycler GeneAmp9700 ABI 
PCR-Cycler Mastercycler eppendorf 
pH-meter  Mettler Toledo 
pipets Reference eppendorf 
plate reader Magellan Tecan 
power supplies PowerPacHC Bio-Rad 
real-time PCR Cycler LightCyclernano 1.0 Roche 
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SDS-PAGE chamber Criterion Bio-Rad 
semi-dry transfer chamber Trans-Blot SD Bio-Rad 
shaker KM-2Akku Edmund Bühler 
shaker K2-50 Noctua 
shaker Titramax 100 Heidolph 
spectrophotomteter Ultrospec3100pro Amersham 
sterile working bench Antares 48 Sterile 
vortexer MS1 IKA 
water bath AL12 Lauda 
 
2.1.2 Software 
ArgusX1  
BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) 
BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) 
CellQuest Pro (BD Biosciences) 
GIMP 2 (www.gimp.org) 
Microsoft Office 2010 
Vector NTI Advance 11 
NCBI database (http://www.ncbi.nlm.nih.gov/) 
MultAlin (http://multalin.toulouse.inra.fr/multalin/) 
Reverse Complement tool (http://www.bioinformatics.org/sms/rev_comp.html) 
 
2.1.3 Consumables 
Table 2: Consumables 
Type Size/Specification Supplier 
bacteria culture tubes 15 ml Falcon 
bacteria culture plates 9 cm Greiner 
cell culture pipets 5,10, 25 ml Greiner 
cell culture plasticware 96-,48-,24-,6-well,T-75 Greiner 
cell culture plasticware 48-,24-,6-well Sarstedt 
cell culture plasticware 4-well Nunc 
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FACS tubes 5 ml Falcon 
gloves nitrile Kimberly-Clark 
LightCycler strips  Roche 
nitrocellulose membrane Hybond-ECL Amersham 
PCR reaction tubes 0.2 ml Biozym 
pipet tips 10, 100, 1000 µl Eppendorf, Biozym, Sarstedt 
reaction tubes 1.5, 2 ml Eppendorf, Sarstedt 
reaction tubes 15, 50 ml Falcon, Sarstedt 
sterile filter units 0.22 µM Millipore 
Whatmanpaper 58x58 cm Schleicher und Schüll 
 
2.1.4 Chemicals 
Often used chemicals were purchased with „pro analysis“ grade and were supplied if not 
otherwise stated by Calbiochem, Fluka, Merck, Sigma and Roth. 
 
Table 3: Buffers and solutions 
Type Compostion / Supplier 
Buffers for agarose gel electrophoresis 
6x DNA loading dye fermentas 
50x TAE 
 
2 M Tris-HCl, pH 8.0, 1 M acetic acid, 
50 mM EDTA 
Lysis buffers for cell extracts 
RIPA buffer (radioimmunoprecipitation 
buffer) 
20 mMTris pH 7.4, 137 mMNaCl, 0.1% SDS, 
0.1 % sodiumdesoxycholate, 1 % Triton X-100, 
10 % glycerol, 2 mM EDTA, 1 mM EGTA, 
1 mMNaF, 20 mM sodiumpyrophosphate plus 
protease and phosphatase inhibitor cocktail 
(Roche) 
Solutions for western blot 
5x Sample buffer 50 mMTris, 2 % SDS, 5 % glycerol, 
5 % β-mercaptoethanol, 0.2 mg/ml bromphenol 
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blue  
10x SDS electrophoresis buffer  250 mM Tris, 188 mM glycine, 3.5 mM SDS 
SDS Transfer buffer 48 mM Tris, 39 mM glycine, 3.5 mM SDS,  
20 % methanol 
Blocking solution TBST with 2 % or 5 % BSA (Roth) 
Blocking solution TBST with 5 % skim milk powder (Sigma) 
TBS 20 mM Tris-HCl, 150 mM NaCl, pH 7.6 
TBST TBS with 0.1 % Tween 20 
Solutions for FACS analysis and immunocytochemistry 
PBS (w/o Mg, Ca) Biochrom 
FACS fixing solution 1 % PFA in PBS 
FACS saponin buffer 0.5 % BSA, 0.5 % saponin, 0.02 % NaN3 in 
PBS 
FACS wash buffer 0.5 % BSA, 0.02 % NaN3 in PBS 
IC blocking buffer 5 % normal goat serum, 0.3 % Triton-X100 in 
PBS 
IC antibodyincubationbuffer 1 %  normal goat serum in PBS 
Mounting medium with DAPI VectaShield 
 
Table 4: Kits 
Type Supplier 
BCA Protein Assay Kit Pierce 
Endo-Free Plasmid Maxi Kit Qiagen 
FastLane cDNA Kit Qiagen 
GFX purification Kit GE healthcare 
Nucleofection Kit V Lonza 
T4 DNA Ligase Kit Promega 
ZYPPY Plasmid Mini Kit Zymo Research 
 
2.1.5 Antibodies 
Antibodies for FACS analysis, immunocytochemistry or western blot. 
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Table 5: Primary antibodies 
Target Type Company Application Dilution 
β-actin mouse monoclonal IgG1 Sigma (AC-15) WB 1:10.000 
Tuj1 mouse monoclonal IgG1 
Santa Cruz  
(sc-51670) 
FACS, IC 1:100 
1:500 
Flag-tag mouse monoclonal IgG1 Sigma (F1804) WB 1:10.000 
GAPDH mouse monoclonal IgG1 Abcam (ab8245) WB 1:10.000 
GAPDH rabbit polyclonal IgG Santa Cruz (FL-335) WB 1:1000 
GFAP rabbit polyclonal IgG Dako (Z0334) 
FACS, IC, 
WB 
1:500 
HuC/D mouse monoclonal IgG1 
Invitrogen 
 (A-21271) 
FACS 
1:100 
HES5 rabbit polyclonal IgG 
Lifespan Biosciences 
(LS-C136917) 
WB 
1:1000 
HES1 rabbit polyclonal IgG abcam (ab71559) WB 1:1000 
Lamin A/C mouse monoclonal IgG1 BD (612162) WB 1:1000 
pGSK3β (Ser9) rabbit polyclonal IgG 
Cell Signaling 
(9336) 
WB 
1:1000 
pSTAT3 
(Tyr705) 
rabbit monoclonal IgG 
Cell Signaling 
(9139) 
WB 
1:2000 
S100β rabbit polyclonal IgG Dako (Z0311) FACS, IC 1:500 
STAT3 
mouse monoclonal 
IgG2a 
Cell Signaling 
(9145) 
WB 
1:2000 
HA-tag mouse monoclonal IgG1 Cell Signaling (6E2) WB 1:10.000 
negative 
control 
normal mouse IgG Santa Cruz (sc-2025) 
FACS, IC 
1:100 
negative 
control 
normal rabbit IgG Santa Cruz (sc-2027) 
FACS, IC 
1:100 
NICD1 
(Val1744) 
rabbit monoclonal IgG 
Cell Signaling 
(4147) 
WB 
1:1000 
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Table 6: Secondary antibodies 
 
2.1.6 Oligonucleotides 
Oligonucleotide sequences were from references if indicated and were obtained from MWG 
Biotech AG or from Qiagen. Stock solutions (100 µM) of primers in water were stored at 
-20 °C. 
 
Table 7: Oligonucleotides for sequencing 
Name Purpose Sequence 5’-3’ 
T7_fw 
Sequencing of pcDNA3.1/HisA 
/ pGEM-T easy 
TAATACGACTCACTATAGGG 
SP6_rc 
Sequencing of pcDNA3.1/HisA 
/ pGEM-T easy 
ATTTAGGTGACACTATAG 
pCAGGS-fw Sequencing of pCAGGS TTCCTACAGCTCCTGGGCAACG 
pCAGGS-rc Sequencing of pCAGGS TCAGATGCTCAAGGGGCTTC 
 
 
non-phospho-β-
catenin 
(Ser33/37/Thr41) 
rabbit polyclonal IgG 
Cell Signaling 
(4270) 
WB 
1:1000 
Target Host Conjugate Company Application Dilution 
rabbit IgG goat Alexa Fluor 680 Invitrogen (A-21076) WB 1:10.000 
mouse IgG goat Alexa Fluor 680 Invitrogen (A-21057) WB 1:10.000 
rabbit IgG goat IRDye 800 Rockland (611-131-122) WB 1:10.000 
mouse IgG goat IRDye 800 Rockland (610-131-003) WB 1:10.000 
mouse IgG goat Alexa Fluor 488 Invitrogen (A11029) FACS, IC 1:1000 
rabbit IgG goat Alexa Fluor 647 Invitrogen (A21245) FACS, IC 1:1000 
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Table 8: Oligonucleotides for cloning 
Target 
name 
Purpose 
Forward primer sequence 5’-3’ 
Reverse primer sequence 5`-3` 
Annealing 
temperature  
hHES1 
pCAGGS-
hHES1 
tctcgagttgaccaccATGCCAGCTGATATAATGGAGAAAAAT 
AGCCAGGGCATTGGTTATCAGTTCCGCCACGG 
64,2 °C 
hHES1 
pCAGGS-
HA-hHES1 
tctcgagttgaccaccATGggctacccatatgatgttccagattacgctCCAGCTGATATAATGGAGAAAAAT 
AGCCAGGGCATTGGTTATCAGTTCCGCCACGG 
51,6 °C 
hHES5 
pCAGGS-
hHES5 
tctcgagttgaccaccATGGCCCCCAGCACTGTG 
AGCCAGGGCATTGGTTATCACCAGGGCCGCC 
64,2 °C 
hHES5 
pCAGGS-
HA-hHES5 
TctcgagTTGACCACCATGGGCTACCCATATGATGTTCCAGATTACGCTGCCCCCAGCACTGTG 
AGCCAGGGCATTGGTTATCACCAGGGCCGCC 
64,2 °C 
ctcgag = XhoI restriction site 
ccannnnnntgg = BstXI restriction site 
 
Table 9: Oligonuclrotides for quantitative real-time PCR 
Gene 
name 
Annealing 
temp. 
 
Ampliconlenght 
[bp]/melting 
temp. [°C] 
Forward primer sequence 5’-3’ 
Reverse primer sequence 5’-3’ 
Reference 
hAXIN2 55 °C 202/86 
AGTCAGCAGAGGGACAGGAA 
AGCTCTGAGCCTTCAGCATC 
Hübner 2010 
hG6PD 55 °C 191/88 
ATCGACCACTACCTGGGCAA 
TTCTGCATCACGTCCCGGA 
http://medgen.
ugent.be/rtpri
merdb/ ID: 
1031 
hGFAP 55 °C 158/84 
CGATCAACTCACCGCCAACA 
GTGGCTTCATCTGCTTCCTGTC 
Böhm et al., 
2003 
hHES1 60 °C 100/88 proprietary 
Qiagen, Cat. 
No. 
QT00039648 
hHES5 55 °C 232/90 
TCAGCCCCAAAGAGAAAAAC 
TAGTCCTGGTGCAGGCTCTT 
Chen et al., 
2006 
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hID1 55 °C 127/86 proprietary 
Qiagen, Cat. 
No. 
QT00230650 
hID3 55 °C 101/86 proprietary 
Qiagen, Cat. 
No. 
QT01673336 
hMASH1 55 °C 66/55 proprietary 
Qiagen, Cat. 
No. 
QT00237755 
 
2.1.7 Vectors 
Table 10: Cloning-, reporter and -expression vectors 
Name 
Insert / 
total size 
[bp] 
Properties Reference 
pCAGGS 4790 PCAG 
J. Luo, 
AKos 
pCAGGS-HES1 984/4790 hHES1 this work 
pCAGGS-HES5 525/4790 hHES5 this work 
pCAGGS-HA-HES1 1011/4790 hHES1 tagged N-terminally with HA-Tag this work 
pCAGGS-HA-HES5 552/4790 hHES5 tagged N-terminally with HA-Tag this work 
pCAGGS-GFP 723/5534 mutGFP, PCAG 
J. Luo, 
AKos 
pCAGGS-NICD1 2500/4790 mouse notch intracellular domain 1 
Addgene 
26891 
pCAGGS-mS33Y β-
catenin-HA 
2387/7178 
mS33Y β-catenin tagged C-terminally with 
HA-Tag 
Hübner et 
al., 2010 
pCAGGS-mWnt3a-
HA 
1116/5842 
 
mWnt-3a tagged C-terminally with HA-
Tag 
Hübner et 
al., 2010 
pGEM-T easy 3015  cloning vector, blue/white screening Promega 
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pCMV6-XL4-HES1 4700 hHES1 
Origene 
SC301536 
pCMV6-XL4-HES5 4700 hHES5 
Origene 
SC116707 
pmaxGFP 3486 PCMV, maxGFP Amaxa 
 
2.1.8 Enzymes 
Enzymes (polymerases, restriction enzymes, ligases, phosphatases) were purchased from 
Promega, New England Bioloabs, Fermentas, Stratagene and Qiagen. 
 
2.1.9 Bacterial strains and media 
As host bacterium the E. coli K12 derived strain JM109 with genotype e14–(mcrA–) recA1 
endA1 gyrA96 thi-1 hsdR17 (rK
–
mK
+
) supE44 relA1 (lac-proAB) [F´ traD36 
proABlacI
q
ZM15] (Promega) was used.  
 
Table 11: Bacterial media 
Type Supplier Composition 
LB-medium Roth 15 g/l H2O, autoclave 
LB-agar Roth 25 g/l H2O, autoclave 
 
If needed for selection, 100 µg/ml ampicillin (Roth) or 25 µg/ml kanamycin (Roth) were 
added after autoclaving. For blue/white screening, 1 mM IPTG (Roth) and X-Gal (Invitrogen) 
were added after autoclaving. 
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2.1.10 Cell lines and media 
Table 12: Eukaryotic cell lines and media 
Line Type Proliferation medium Reference 
HEK293H human embryonic kidney DMEM 4.5 g/l glucose 
10 % FCS 
1x Pen/Strep 
Invitrogen 
ReNcell VM human ventral-midbrain 
derived neural precursor 
cells, v-myc immortalized 
DMEM/F12 
10 ng/ml bFGF 
20 ng/ml EGF 
2 mMGlutaMax, 
1xB27, 10 U/ml heparin 
sodium salt, 50 µg/ml 
gentamycin 
ReNeuron/Millipore 
iPS-NPC iPS-derived Neural 
progenitor cells 
(Human iPS cell line 
hFib2-iPS5; Park et al., 
2008) 
DMEM/F12; 
Neurobasal Medium 1:1 
1x N2 supplement 
1x B27 
2 mMGlutaMax, 0,25x 
Pen/Strep 
10 ng/ml bFGF/EGF 
Derived from 
hFib2-iPS5; 
(Park et al., 2008) 
NPCs derived by: 
Dr. R. Hübner as 
described (Trilck et 
al., 2013)  
 
2.1.11 Cell culture media, buffers and supplements 
Table 13: Culture media and buffers 
Type Supplier 
B27 Invitrogen 
Benzonase Merck 
bFGF Roche/ GlobalStem 
DMEM (Dulbecco`s Modified Eagle 
Medium) 4.5 g/l glucose 
Invitrogen 
DMEM/F12 Invitrogen 
EGF Roche 
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FCS (fetal calf serum) Invitrogen 
Gentamycin Invitrogen 
HBSS (Hank`s balanced salt solution) Invitrogen 
heparin sodium salt Invitrogen 
HSA (human serum albumin) OctaPharma 
mouse laminin Trevigen 
N2 Invitrogen 
Neurobasal medium Invitrogen 
noggin Fc- chimera R&D 
normal goat serum Invitrogen 
Pen/Strep 100x PAA 
Poly-D-ornithine Sigma 
Poly-L-ornithine Sigma 
Trypsin/Benzonase solution 25 U/ml Benzonase in Trypsin-EDTA  
Trypsin/EDTA  Invitrogen 
Trypsin-Inhibitor Sigma 
Trypsin-inhibitor/Benzonase 1 % HSA , 25 U/ml Benzonase, 0,55 mg/ml 
trypsin-inhibitor in DMEM/F12 
 
If not dissenting indicated supplements were used with following concentrations. 
Table 14: Supplements 
Substance Solvent Stock Solution End Solution Supplier 
AB199 (IM12) DMSO 10 mM 3 µM M. Beller, LIKAT 
AICAR H2O 250 mM 1 mM Santa Cruz 
DAPT DMSO 10 mM 5 µM Sigma 
DMSO  100 % 
depending on 
compared substance 
(0,2 % -4 %) 
Sigma 
Dorsomorphin DMSO 10 mM 1 µM Sigma 
HSA PBS 0,1 % 0,001 % OctaPharma 
Jak-Inhibitor-1 DMSO 1 mM 1 µM Santa Cruz 
recombinant HSA 100 µg/ml 400 ng/ml R&D 
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human Dkk1 
recombinant 
human Noggin 
PBS 250 µg/ml 500 ng/ml R&D 
recombinant 
human sFRP1 
HSA 100 µg/ml 500 ng/ml R&D 
recombinant 
mouse Wnt-3a 
HSA 100 µg/ml 100 ng/ml R&D 
SB216763 DMSO 10 mM 3 µM Sigma 
SB431542 DMSO 10 mM 20 µM Sigma 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cultivation of ReNcell VM cells 
ReNcell VM cells were initially provided by ReNeuron (Guildford, UK) and are distributed 
now from Millipore (Billerica, USA). It is a v-myc retrovirally immortalized human cell line 
and was derived from the ventral midbrain of a 10-week old male fetus. The cells were 
cultivated in cell culture flasks at 37 °C with 5 % CO2 and 20 % O2. For growing as adherent 
monolayers cell culture flasks needed to be coated with Laminin (10 µg/ml). For coating it 
was diluted 1:100 in ice-cold DMEM:F12 and incubated with culture plastic ware for at least 
one hour at 37 °C. Laminin was removed by washing with pre-warmed DMEM:F12. Cells 
were cultivated in proliferation medium and passaged when reaching around 70 % 
confluence. Therefore, cells were washed with pre-warmed HBSS and incubated with 
Trypsin/Benzonase until detaching. Reaction was stopped by adding Trypsin 
inhibitor/Benzonase. The suspension was centrifuged for 5 min at 100 x g at room 
temperature. The supernatant was discharged and the cell pellet was resuspended in pre-
warmed proliferation medium. A defined number (Table 15) of cells were seeded in Laminin 
coated culture vessels.  
Differentiation was induced by withdrawal of growth factors. Therefore, cells were washed 
with pre-warmed HBSS and incubated with differentiation medium at 37 °C for up to 3 days. 
ReNcell VM cells are able to differentiate into neurons, astrocytes and oligodendrocytes 
(Donato et al., 2007, Hübner et al., 2010 and Morgan et al., 2010). 
 
2.2.1.2 Cultivation of HEK293H 
HEK293H cells were grown as adherent monolayers at 5 % CO2, 20 % O2 at 37 °C and were 
passaged when reaching around 80 % confluence. Cells were washed with pre-warmed PBS 
(Biochrom) and incubated with Trypsin/EDTA (Invitrogen) until detaching. Reaction was 
stopped by adding medium. The suspension was centrifuged for 5 min at 100 x g at room 
temperature. The supernatant was discharged and the cell pellet was resuspended in pre-
warmed medium. A defined number (Table 15) of cells were seeded in culture vessels. 
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2.2.1.3 Cultivation of iPS cell derived neuronal progenitor cells (iPS-NPCs) 
Human iPS cell line hFib2-iPS5 (Park et al., 2008), was maintained on a layer of mitotically 
inactivated murine embryonic fibroblasts (GlobalStem) and cultured as described (Trilck et 
al., 2013) and manually passaged every 5-7 days. iPS routine cell culture was carried out by 
Michaela Trilck and Rayk Hübner (AKos). 
iPS-NPCs were derived via dual SMAD inhibition. Cells were obtained after 10 days of 
differentiation in N2B27 medium containing Neurobasal, DMEM/F12, 1xN2 supplement, 
1xB27 supplement and GlutaMax (all from Invitrogen) complemented with human 
recombinant noggin Fc- chimera (500 ng/ml; R&D) and SB431542 (20 μM; Sigma). After 10 
days, Noggin and SB431542 were omitted from the medium and 10 ng/ml hEGF (Roche) and 
hFGF-2 (GlobalStem) were included. After 14 days appearing rosette clusters were manually 
isolated using a hooked glass needle. Clusters were gently triturated using Tryp/Benz and 
reaction was stopped with Trit/Benz. iPS-NPCs were cultured on Poly-L-ornithin (15 µg/ml) 
/Laminin (10 µg/ml) coated dishes for 3–5 days (medium was changed every day) until 70 % 
confluence and passaged as described (2.2.1.1). Differentiation was induced by washing the 
cells with HBSS followed by withdrawal of growth factors FGF2 and EGF from the medium 
at a confluence of 70 %.  
 
2.2.1.4 Cultivation of E. coli 
E. coli was cultivated at 37 °C and 200-250 rpm on a rotatory shaker in LB-medium with 
appropriate antibiotics in Erlenmeyer vials or polystyrene tubes. For storage of bacterial 
clones 0.8 ml of culture was mixed with 0.2 ml glycerol and stored at -80 °C. For seeding, a 
small amount of the glycerol stock was added into 5 ml of fresh LB medium with appropriate 
antibiotics. 
 
2.2.1.5 Measuring and seeding of cell numbers  
For cell number measurement 50 µl of cell suspension was added to 10 ml CASYton and 
analyzed by CASY cell counter (Innovatis, Reutlingen, Germany) with the appropriate 
program. The seeded cell numbers are shown in Table 15. 
 
Materials and Methods  34 
 
 
Table 15: Seeding cell numbers 
Cell line Vessel size Cell number/ 
Experiment 
Proliferation time 
ReNcell VM 6-well (greiner) 250.000/treatment 
350.000/transfection 
48 h 
ReNcell VM 4-well (Nunc) 
24-well (greiner) 
100.000/treatment 
150.000/transfection 
24 h 
ReNcell VM 96-well (greiner) 5.000/treatment 48 h 
HEK293H 4-well (Nunc) 
24-well (greiner) 
200.000/transfection 24 h 
iPS-NPCs 4-well (Nunc) 
24-well (greiner) 
 24 h 
iPS-NPCs 6-well (greiner)  48 h 
 
2.2.1.6 Transfection of ReNcell VM cells 
ReNcell VM cells were transfected by Nucleofaction (Lonza, Cologne, Germany). Briefly, 
cells were resuspended in 100 µl of Nucleofection solution (Kit V) mixed with 2-4 µg 
plasmid/1 Mio cells and transfected with program X-001 according to the manufacturer´s 
instructions. Cells were plated on Laminin coated vessels up to 70 % confluence and were 
differentiated upon withdrawal of growth factors. The transfection efficiency was about 90 % 
using positive control pmaxGFP (Lonza) as judged by microscopy (see appendix 7.1). 
 
2.2.1.7 Transfection of HEK293H cells 
For Transfection of HEK293H cells, 24 h cultivated cells were washed with pre-warmed PBS 
and incubated with medium without antibiotics (Table 15). 2 h later cells were transfected 
with 1 to 2 µg of plasmid with Lipofectamine 2000 according to the manufacturer´s 
instructions. After 6 h of incubation at 37 °C, medium was changed to medium containing 
antibiotics. The transfection efficiency was about 95 %, using positive control pCAGGS-GFP 
as judged by microscopy (see appendix 7.1).  
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2.2.1.8 Transformation and selection of E. coli 
50 µl of competent cells were thawed on ice and 1 to 5 µl of DNA was added, incubated on 
ice for 5 min, plated onto LB-agar plates (37 °C) with appropriate antibiotics and incubated 
overnight at 37 °C in an incubator (Heraeus, Hanau, Germany). For blue/white screening, 
1 mM IPTG and X-Gal were added to agar medium. For selection of transformed cells, single 
white colonies were picked, grown overnight in 6 ml LB-medium with appropriate antibiotics 
and were further analyzed.  
 
2.2.1.9 Treatment of cells 
For treatment of ReNcell VM cells and NPCs, cells were washed with pre-warmed HBSS. 
Differentiation was induced by withdrawal of growth factors and simultaneously cells were 
treated - if not otherwise indicated - once with substances (Table 14). In experiments using 
iPS-NPCs, medium was changed every 2 days, without additional treatment. 
 
2.2.1.10 WST-1 assay 
For cell viability measurement the colorimetric assay WST-1 (Roche, Penzberg, Germany) 
was used that determines the enzyme activity of mitochondrial dehydrogenases, which cleave 
a tetrazolium substrate resulting in colored formazan. The enzyme activity correlates with the 
metabolic activity of viable cells (Hipper and Isenberg, 2000). 5.000 ReNcell VM cells were 
plated on Laminin coated 96-well plates in proliferation media and treated after 4 hours of 
incubation at 37 °C with substances. Cell viability was analyzed after 48 h by adding 10 µl 
WST-1 reagent per well and 2 h incubation at 37 °C. The optical density at 450 nm 
wavelength was determined using genios microplate reader (Tecan, Crailsheim, Germany). 
650 nm was used as reference wavelength. Six wells per condition were measured. 
 
2.2.2 Protein analysis 
2.2.2.1 Preparation of total cell lysates and protein measurement 
Cells were harvested as described and lysed in ice cold RIPA buffer containing protease and 
phosphatase inhibitor cocktails (Roche) for 15 min on ice, slightly shaking. Suspension was 
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centrifuged at 15.000 g for 15 min at 4 °C and the supernatant was stored at -80 °C. Protein 
concentrations were measured using the bicinchoninic acid assay (BCA, Pierce, Rockford, IL, 
USA) according to manufacturer`s instructions using a plate reader (Tecan). 
 
2.2.2.2 Preparation of nuclear cell lysates  
Cells were washed twice with ice-cold PBS and then harvested with 1 ml ice-cold PBS, 
scraped with a cell scraper and centrifuged for 10 sec. The pellet was triturated 5 times with 
1 ml ice-cold 0.1 % NP40-PBS, the remainder was pop-spun for 10 sec and the supernatant 
was transferred in a new tube, this was the cytoplasmic fraction. Next, the pellet was 
resuspended with 1 ml ice-cold 0.1 % NP40-PBS, afterwards, the remainder was centrifuged 
for 10 sec and the supernatant was discarded. For SDS-PAGE sample preparation, remaining 
pellets were mixed with 200 µl 1x sample buffer, sonificated twice for 5 sec, placed on ice 
and were subsequently boiled for 5 min. 
 
2.2.2.3 Western blot 
For protein analysis via western blot a defined amount of protein was mixed with 5x sample 
buffer and incubated for 5 min at 95 °C. Samples were loaded on a vertical Tris-HCl gel with 
4-15 % acrylamide concentration gradient (Criterion Precast, Bio-Rad) and were run in a 
Criterion Cell (Bio-Rad) at 100-120 V until the running front of the gels reached the bottom. 
The prestained peqGOLD marker IV (PEQLAB, Erlangen, Germany) was used as molecular 
weight marker. Proteins were transferred via a Semi-dry blotting system (Trans-BlotSD, Bio-
Rad) onto nitrocellulose membranes (Hybond-ECL, Amersham) at 200 mA for 1,5 h. 
Membranes were blocked with blocking solution (2 % BSA or 5 % milk) in TBST for 1 h 
followed by incubation with primary antibodies overnight at 4 °C on a shaker. Blots were 
washed 3 times for 5 min with TBST and incubated in darkness with appropriate fluorescent 
secondary antibodies for 1 h. Afterwards membranes were washed 3 times for 5 min with 
TBS, air-dried and stored in the dark. To visualize and quantify proteins the Odyssey infrared 
imaging system (LI-COR Biosciences GmbH, Bad Homburg, Germany) was used. The 
membranes were scanned at a wavelength of 700 nm for Alexa Fluor 680-labeled antibodies 
and at a wavelength of 800 nm for IRDye 800CW-labeled antibodies, respectively using 
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Odyssee software version 1.2. Values from total cell lysates were normalized to GAPDH 
which was used as a loading control. Nuclear cell lysates were normalized to Lamin A/C.  
 
2.2.2.4 FACS analysis 
To analyze proteins in different cell populations FACS analysis was used. Therefore cells 
were differentiated in 6-well plates, harvested and fixed with 1 % PFA in PBS for 15 min at 
room temperature. After centrifugation at 100 x g at 4 °C, the pellet was resuspended in 
500 µl FACS-Wash buffer and stored at 4 °C. 
For staining, cells were centrifuged at 100 x g at 4 °C and the pellet was resuspended in 25 µl 
saponin buffer containing diluted primary antibodies and incubated for two hours at room 
temperature on a shaker. As negative control, cells were incubated with normal mouse and 
normal rabbit IgG. Cells were washed with 300 µl saponin buffer and resuspended in 25 µl 
saponin buffer containing appropriate secondary antibodies. The samples were incubated for 
one hour in darkness at room temperature with gentle shaking. Cells were washed with 300 µl 
saponin buffer, resuspended in 500 µl FACS wash buffer and stored in the dark at 4 °C until 
analysis. 
50.000 cells per sample were counted and analyzed using FACSCalibur (BectonDickinson, 
San Jose, USA) in combination with CellQuest Pro software. Cell debris was filtered out of 
the data set prior to analysis. Gates were set referred to cells stained with negative control 
antibodies. 
 
2.2.2.5 Immunocytochemistry 
For immunocytochemistry cells were cultured on coverslips and fixed on them with 4 % PFA 
in PBS for 15 min at room temperature. Afterwards, cells were washed with PBS and 
conserved with 0.02 % NaN3 in PBS at 4 °C. Following blocking and permeabilization with 
IC blocking buffer for 30 min, cells were incubated for 30 min with primary antibodies 
diluted in IC antibody incubation buffer. Cells were washed 3 times with PBS and incubated 
for 30 min at room temperature in darkness with secondary antibodies diluted in IC antibody 
incubation buffer. Afterwards, cells were washed with PBS and covered with mounting 
medium containing DAPI (VectaShield). Slips were plated on object plates, sealed using nail 
polish and stored at 4 °C in the dark until analysis. Staining without primary antibodies served 
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as a control for background staining. Fluorescent images were generated by using a Biozero 
microscope (Keyence). 
 
2.2.3 Molecular biological methods 
2.2.3.1 Polymerase chain reaction (PCR) 
For primer testing colony PCR and optimizing PCR conditions HotStartTaq (Qiagen) was 
used in combination with the gradient cycler (Eppendorf). For cloning purposes the 
proofreading blend Herculase II (Stratagene, La Jolla USA) was used in combination with the 
ABI cycler. Colony PCR was run with HotStartTaq on the ABI cycler in combination with the 
sequencing primers for pCAGGS (Table 7). 
 
Table 16: PCR Mixes 
Compound HotStartTaq Herculase II 
buffer - 5 µl (5 x) 
enzyme 10 µl (MasterMix) 0,25 µl (5 U/µl) 
dNTPs (10 mM) - 0,5 µl 
primer (10 pmol/µl) 0,8 µl 1 µl 
template (ca. 10 ng/µl) 1 µl 2 µl 
H2O 7,2 µl 15 µl 
DMSO 1 µl 1,25 µl 
 
Table 17: Cycling conditions 
Cycler  Eppendorf (HotStartTaq) ABI (Herculase II) 
Step Temperature Time Temperature Time 
denaturation 95 °C 15 min 98 °C 4 min 
denaturation 94 °C 30 sec 98 °C 20 sec 
annealing 60±10 °C 30 sec see Table 8 20 sec 
extension 72 °C 60 sec 72 °C 23 sec 
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2.2.3.2 Agarose gel electrophoresis 
To generate gels, 1-2 % agarose (Biozym) was dissolved in 1xTAE buffer and heated in a 
microwave. Ethidium bromide (1 µg/ml working concentration) was added and gels were 
poured into prepared gel chambers. DNA samples were mixed with appropriate volume of  
6x loading dye (Fermentas, St.-Leon-Roth, Germany). Gels were run at 100 V and 
photographed using UV gel documentation system (Herolab/biostep) in combination with a 
digital camera sytem (C-5050; Olympus, Japan). Size estimation of DNA fragments was done 
by using the GeneRuler DNA Ladder Mix (Fermentas). 
 
2.2.3.3 Isolation and purification of DNA 
To isolate vectors from E. coli cultures, the ZYPPY Plasmid Mini Kit (Zymo Research) was 
used. 6 ml of culture were centrifuged for 5 min at 14.000 g at room temperature and 
processed according to manufacturer’s instructions. For large-scale purification of DNA, the 
Endo-Free Plasmid Maxi Kit (Qiagen, Hilden, Germany) was used according to 
manufacturer`s instructions. DNA was resuspended in endotoxin-free TE-buffer to yield a 
concentration of ~1 µg/µl. Vectors were sterile filtered (0.22 µM) and stored at -20 °C. 
For purification of DNA fragments from solutions or gels, the GFX purification Kit (GE 
healthcare, Munich, Germany) was used according to manufacturer’s instructions. DNA was 
eluted in 30 µl H2O.  
 
2.2.3.4 Photometric DNA concentration measurement 
DNA concentration and purity was estimated by measuring absorption at 260 and 280 nm 
using a spectrophotometer (Ultrospec 3100pro, Amersham, Munich, Germany).  
 
2.2.3.5 Digestion, dephosphorylation and ligation of DNA  
For digestion the FastDigest enzymes (Fermentas) were used. Therefore 500 ng of DNA was 
incubated with 0,5 µl of each enzyme together with appropriate amount of buffer and water 
for 20 min at 37 °C.  
Materials and Methods  40 
 
 
To avoided re-ligation, vectors were dephosphorylated by adding 1 µl of calf intestine 
alkaline phosphatase (CIAP, Promega, USA) and appropriate amount of reaction buffer and 
were incubated for 30 min at 37 °C. 
For ligation, 50 ng of linearized and dephosphorylated vector together with a 3-fold molar 
amount of fragment were incubated overnight at 4 °C or for 4 h at room temperature with  
T4 DNA ligase (T4 DNA Ligase Kit, Promega) 
 
2.2.3.6 Sequencing of DNA 
To check the identity of DNA, the purified DNA samples were sequenced at Qiagen 
Sequencing Service (Qiagen, Hilden) or MWG (eurofinsmwg|operon, Ebersberg). Sequences 
were aligned and analyzed using MultAlin software. 
 
2.2.3.7 cDNA synthesis 
To generate cDNA the FastLane cDNA Kit (Qiagen) was used according to manufacturer’s 
instructions. Briefly, cells were grown in a 24 or 96-well plate and were washed with 200 µl 
or 100 µl FCW buffer, respectively. After 10 min incubation with 80 µl or 16 µl FCP buffer, 
lysates were stored at -80 °C. The lysates were used to synthesize cDNA according to 
manufacturer’s instructions with the exception, that only half amount of the buffers was used 
per sample due to cost-effective reasons. 
 
2.2.3.8 Quantitative real-time PCR (qRT-PCR) 
For quantitative real-time PCR a LightCycler Nano 1.0 (Roche) was used in combination with 
FastStart Essential DNA Green Master Mix (Roche) according to manufacturer’s instructions. 
For primer information see Table 9. The primer efficiency was calculated by plotting the Cq-
values against the cDNA amounts of a serial diluted positive control (human total brain 
cDNA, Clontech). As a template, 1 µl cDNA generated with FastLane Cell cDNA Kit 
(Qiagen) was used. All samples were run in duplicates and as a negative control template was 
omitted from the reaction. For cycling parameters see Table 18. PCR products were verified 
by melting point analysis and by size in agarose gel electrophoresis. Relative changes of 
mRNA amount were calculated using the delta-delta Ct method (Pfaffl et al., 2000). Amount 
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of mRNA of interest was normalized to the housekeeping gene Glucose-6-phosphate-
dehydrogenase (G6PD) and was calculated as relative changes compared to control. 
 
Table 18: Cycling parameters 
Step Temperature Time 
denaturation 95°C 10 min 
denaturation 95 °C 20 sec 
annealing See Table 9 20 sec 
extension 72 °C 23 sec 
melting curve 60-95 °C  
 
2.2.3.9 Statistical analysis  
Statistical evaluation was carried out using the two-tailed Student’s t-test with Excel software 
(Microsoft, USA). Difference was considered to be statistically significant p ≤ 0.05. 
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3 Results 
3.1 Generation of expression vectors 
For overexpression in ReNcell VM cells the backbone plasmid pCAGGS was used. pCAGGS 
contains a CAG promoter (Niwa et al., 1991) which has been shown to drive efficient 
expression in ReNcell VM cells compared to other promoters like CMV (Hübner et al., 2010 
and data not shown). In addition, HA-HES plasmids were generated (see appendix 7.1). 
 
3.1.1 Generation of pCAGGS-hHES1 
To amplify hHES1 the plasmid pCMV6-XL4-HES1 (Origene) was used as a template, 
together with the forward primer which includes the XhoI restriction site and the reverse 
primer which includes the BstXI restriction site. After amplification of hHES1 (Figure 9, A) 
the insert was purified and ligated into pGEM-T easy (Promega) for subsequent blue/white 
screening and selection. Positive clones were analyzed by digestion with EcoRI, expected 
fragments were ca. 3000 bp and 981 bp (Figure 9, B). All positive clones were sequenced and 
used for insert production. The purified insert was ligated into pCAGGS and resulting clones 
were analyzed by colony PCR. Consequential positive clones were sequenced and transfected 
in ReNcell VM cells. The expression of HES1 was tested via western blot analysis. Therefore, 
transfected ReNcell VM cells were proliferated for 24 h after transfection and then 
differentiated for 24 h. Western blot analysis revealed a specific band at ca. 25 kDa (Figure 9, 
D). The predicted size of hHES1 is 30 kDa, the variance may be due to alternative splicing of 
HES (Hirata et al., 2000).  
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Figure 9: Generation ofpCAGGS-hHES1. A: Product of hHES1 amplification (M=DNA ladder). B: Digestion 
of pGEM-T easy-hHES1 by EcoRI; expected fragments were 3000 bp and 981 bp. C: Plasmid map of pCAGGS-
hHES1. D: Western blot of pCAGGS-hHES1 transfected ReNcell VM cells after 24 h of differentiation, 
pCAGGS-GFP transfected cells were used as control and GAPDH as loading control. 
 
3.1.2 Generation of pCAGGS-hHES5 
To amplify hHES5 the plasmid pCMV6-XL4-HES5 (Origene) was used as a template, 
together with the forward primer which includes XhoI restriction site and the reverse primer 
which includes a BstXI restriction site. After amplification of hHES5 (Figure 10, A) the insert 
was purified and ligated into pGEM-T easy (Promega) for subsequent blue/white screening 
and selection. Positive clones were analyzed by digestion with EcoRI, expected fragments 
were ca. 3000 bp and 550 bp (Figure 10, B). All positive clones were sequenced and used for 
insert production. The purified insert was ligated into pCAGGS and resulting clones were 
analyzed by colony PCR. Consequential, positive clones were sequenced and transfected in 
ReNcell VM cells. The expression of Hes5 was tested via western blot analysis. Therefore, 
transfected ReNcell VM cells were proliferated for 24 h after transfection and then 
differentiated for 24 h. Western blot analysis revealed a specific band at ca. 20 kDa (Figure 
10, D). This fits to the predicted size of 19 kDa of hHES5. 
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Figure 10: Generation of pCAGGS-hHES5. A: Product of hHES5 amplification (M=DNA ladder). 
B: Digestion of pGEM-T easy-hHES5 with EcoRI; expected fragments were 3000 bp and 550 bp. C: Plasmid 
map of pCAGGS-hHES5. D: Western blot of pCAGGS-hHES5 transfected ReNcell VM cells after 24 h of 
differentiation, pCAGGS-GFP transfected cells were used as control and GAPDH as loading control. 
 
3.2 The Notch pathway in ReNcell VM cells 
It was shown before in several different organisms and cell lines, that the Notch pathway is 
decidedly important in the neuronal differentiation (Ables et al., 2011). The main point in 
Notch activation is the release of the Notch intracellular domain by cutting the Notch receptor 
with a γ-secretase. To demonstrate an active Notch pathway in differentiating ReNcell VM 
cells, the γ-secretase activity was inhibited by the widely used small molecule DAPT (N-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester) as shown before in other 
systems (Ong et al., 2006, Nelson et al., 2006). It inhibits not only the release of the Notch 
intracellular domain but also affects other γ-secretases, which can lead to multifarious 
ramifications (Bay and Pfaff 2011). Therefore, cells were differentiated and simultaneously 
treated with 5 µM DAPT (Hübner, 2010) at 0 h. In addition, in other experiments, the Notch 
pathway was activated by overexpression of Notch intracellular domain 1 (NICD1). NICD1 
was described as the most prominent Notch intracellular domain in mice neuronal cells (Ables 
et al., 2010). The following experiments were performed to elucidate the impact of Notch 
signaling on the cell fate of differentiating ReNcell VM cells. 
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3.2.1 Inhibition of the Notch pathway 
Treatment of ReNcell VM cells with DAPT for 3 days of differentiation led to an increased 
net like growth pattern (Figure 11, A), which was not observable in control treated cells 
(solvent DMSO). Western blot analysis showed a decrease of endogenous NICD1 level after 
3 h of DAPT treatment, while the control protein level GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) was not affected (Figure 11, B).  
The main target genes of the Notch pathway are the basic helix-loop-helix (bHLH) 
transcription factors hairy and enhancer of split 1 and 5 (HES1 and HES5; Bailey et al., 
1995). Both are expressed in ReNcell VM cells and were able to be down regulated by DAPT 
treatment (Figure 11, C and D). Strikingly the HES1 mRNA level was less affected than the 
HES5 level. NICD seemed to have a stronger effect on HES5 than on HES1 regulation. 
Furthermore, both target genes responded fast (already after 2 h of treatment) and continuing 
(up to 72 h of treatment), which suspects a direct and permanent regulation. A detection of the 
endogenous HES1 and HES5 protein level reduction via western blot was, due to the low 
protein level, not possible. 
HES1 and HES5 are described to induce the glial fibrillary acidic protein (GFAP) (Kabos et 
al., 2004, Kamakura et al., 2004) and reduce expression of proneural genes like MASH1 
(ASCL1), Neurogenin 1, and Neurogenin 2 (Castella et al., 1999, Kageyama 2009). DAPT 
was able to decrease the GFAP mRNA level after 12 h up to 72 h of treatment (Figure 11, E). 
This indicated a indirect regulation of GFAP by DAPT over the Notch target genes HES1 
and/or HES5 in ReNcell VM cells. Upregulation of MASH1 mRNA by DAPT after 6 h up to 
24 h of treatment also indicated a indirect regulation of MASH1 by HES1 and/or HES5. The 
detection of Neurogenin 1 and 2 mRNA levels in ReNcell VM cells via qRT-PCR was not 
possible due to very low mRNA level (data not shown).  
Thus, DAPT was able to inhibit the endogenous Notch pathway in ReNcell VM cells 
apparently by reduction of NICD1, which leads to a reduction of the Notch target genes HES1 
and HES5. Moreover, DAPT was able to reduce GFAP and induce MASH1 mRNA levels.  
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Figure 11: Inhibition of the Notch pathway by DAPT. Analysis of ReNcell VM cells in differentiation A: 
Phase contrast of 3 days differentiated cells treated with DMSO or DAPT, respectively. Scale bar 100 µm. B: 
Western blot analysis of Notch intracellular domain 1 (NICD1) under 3 h DAPT treatment. C-F: qRT-PCR of 
HES1 (C), HES5 (D), GFAP (E) and MASH1 (F) in cells treated with DAPT. Data are normalized to DMSO 
treated cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.2.2 Activation of the Notch pathway 
The plasmid pCAGGS-NICD1 encoded for the cleaved Notch intracellular domain 1 
(110 kDa) and therefore was used to activate the Notch pathway. It was transfected in 
ReNcell VM cells and the overexpression of NICD1 was validated by western blot using a 
specific antibody against NICD1 after 24 h of transfection (Figure 12, A). The NICD1 
antibody detects endogenous levels of the Notch intracellular domain 1 only when released by 
cleavage between Gly1753 and Val1754. qRT-PCR analysis revealed at the same time point 
an 2-fold induction of HES5 and a slightly reduction of HES1 mRNA levels (Figure 12, B). 
Therefore, HES5 seems to be the main target of the Notch intracellular domain 1. 
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To demonstrate the Notch specificity of the DAPT effect, a rescue experiment was performed. 
Therefore, NICD1 and GFP as control were overexpressed in ReNcell VM cells for 3 days of 
differentiation. Simultaneously, the cells were treated with DAPT or DMSO as control. The 
percentage of cells positive for the neuronal marker HuC/D and Tuj1 or the stem cell/ glial 
marker GFAP were measured by flow cytometry. DAPT treatment of GFP transfected control 
cells showed a clear increase in the percentage of cells positive for the neuronal marker 
HuC/D and Tuj1 (Figure 12, C and D). The amount of cells positive for HuC/D increases 
from 8 % up to 23 % and cells positive for Tuj1 from 3 % up to 15 %. Under DAPT treatment 
the percentage of GFP transfected control cells positive for GFAP was not significantly 
affected, but clearly decreased by tendency (Figure 12, E). Conversely, activation of Notch 
signaling via overexpression of NICD1 in ReNcell VM cells resulted in a reduction of cells 
positive for the neuronal marker HuC/D and Tuj1 (Figure 12, C and D). The amount of 
DMSO treated cells positive for HuC/D decreased from 8 % (GFP transfected control cells) to 
4 % (NICD1 transfected cells), cells positive for Tuj1 decreased from 3 % (GFP transfected 
control cells) to 1 % (NICD1 transfected cells). In contrast, an induction of GFAP positive 
cells by NICD1 overexpression was not observable (Figure 12, E). The increase of cells 
positive for neuronal marker by DAPT treatment could be prevented by NICD1 
overexpression (Figure 12, C and D). In this case, the induction was reduced to nearly control 
levels of positive cells. Furthermore, the percentage of DAPT treated cells positive for GFAP 
was induced by NICD1 transfected cells compared to GFP transfected cells. A regulation of 
the glial marker S100β was not observable (data not shown). 
In summary, the NICD1 overexpression was able to activate the Notch pathway by increasing 
HES5 mRNA level. In addition, DAPT was able to induce cells positive for neuronal markers 
like HuC/D and Tuj1 and reduced cells positive for GFAP by tendency. NICD1 
overexpression largely abolished the DAPT effect on differentiating ReNcell VM cells and 
therefore underscores the specificity of DAPT as an inhibitor of the Notch pathway.  
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Figure 12: Activation of the Notch pathway in ReNcell VM cells rescued neuronal differentiation. A: 
Western blot analysis of Notch intracellular domain 1 (NICD1) of cells transfected with pCAGGS-NICD1 or 
control vector pCAGGS-GFP, harvested after 24 h of differentiation. B: qRT-PCR of HES1 and HES5 in NICD1 
transfected cells, harvested after 24 h of differentiation. Data are normalized to GFP transfected cells (indicated 
as black line). C-E: Flow cytometric data showing percentages of NICD1 or GFP transfected cells positive for 
HuC/D (C), Tuj1 (D) and GFAP (E) differentiated for 3 days in the presence of DAPT or DMSO as control. 
Data are presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, *** 
p<0.001 compared to time point control. 
 
3.3 The effect of Wnt-3a in the differentiation of ReNcell VM cells 
As previously shown, Wnt-3a overexpression was able to increase the neuronal differentiation 
in ReNcell VM cells (Hübner et al., 2010). To verify this result, ReNcell VM cells were 
treated with 100 ng/ml of recombinant Wnt-3a and the expression of the neuronal markers 
HuC/D and Tuj1, the mature glial marker S100β and the stem/glial marker GFAP were 
analyzed after 3 days of differentiation via flow cytometry.  
Wnt-3a treatment resulted in an increase in neuronal marker HuC/D (Figure 13, A) from 8 % 
up to 13 % and in an increase of Tuj1 positive cells (Figure 13, B) from 5 % up to 8 %. The 
glial marker S100β was not significantly affected by Wnt-3a treatment (Figure 13, C). 
Simultaneously, the percentage of cells positive for GFAP decreased under Wnt-3a treatment 
(Figure 13, D) from 74 % to 60 %. 
In summary, Wnt-3a treatment was able to induce neurogenesis in ReNcell VM cells and 
coincidentally reduced the stem/glial marker GFAP, while S100β was not significantly 
affected. 
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Figure 13: Induction of neurogenesis in ReNcell VM cells by Wnt-3a treatment. Flow cytometric data 
showing percentages of Wnt-3a treated cells positive for HuC/D (A), Tuj1 (B), S100β (C) and GFAP (D) 
differentiated for 3 days in the presence of Wnt-3a or HSA as control. Data are presented as means ± SEM from 
at least three independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.3.1 Modulation of the Notch target genes by Wnt-3a 
To get a deeper insight into the regulation of the Notch target genes by Wnt-3a, a time series 
analysis was performed in which differentiating ReNcell VM cells were treated for 1 h up to 
72 h with 100 ng/ml of Wnt-3a. Afterwards, an analysis of the mRNA levels of HES1, HES5, 
GFAP and MASH1 was performed by qRT-PCR (Figure 14).  
Wnt-3a treatment resulted in an increase of HES1 at 2 h, 6 h and 8 h but this effect was lost in 
later time points where no regulation was detected (Figure 14, A). In contrast, HES5 was 
rapidly downregulated by Wnt-3a after 2 h up to 24 h except of 8 h and 12 h of treatment 
(Figure 14, B) with a surprisingly strong regulation after 24 h. Interestingly, HES5 mRNA 
levels seemed to oscillate under Wnt-3a treatment, in combination with a time frame without 
significantly regulation between 8 h and 12 h. After 30 h up to 72 h a regulation was no 
longer observable. Strikingly, GFAP mRNA levels were significantly downregulated not until 
6 h but constantly up to 72 h of treatment with exception of 20 h and 30 h. The proneural gene 
MASH1, in contrast, was upregulated after 24 h of Wnt-3a treatment, interestingly at the same 
time point when the strongest HES5 mRNA downregulation was observed.  
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In summary, Wnt-3a was able to induce HES1 mRNA level only in early time points while 
HES5 mRNA level was downregulated. Both Notch target genes seemed to be directly 
affected by Wnt-3a but were differentially regulated in time span and direction. The later 
regulation of GFAP led to the suggestion, that GFAP is an indirect target of Wnt-3a. The 
potentially mediator of this effect is HES5, because of its fast and continuous downregulation 
compared to HES1. Simultaneously, MASH1 was upregulated after 24 h of Wnt-3a treatment, 
which was the same time point when Wnt-3a had a strong effect on HES5 mRNA level.  
 
 
Figure 14: Modulation of Notch target genes in ReNcell VM cells by Wnt-3a. qRT-PCR of HES1 (A), HES5 
(B), GFAP (C) and MASH1 (D) in cells treated with Wnt-3a. Data are normalized to HSA treated cells (time 
point control, indicated as black line). Data are presented as means ± SEM from at least three independent 
experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.3.2 The additive effect of Wnt-3a treatment and Notch inhibition 
Due to the fact that DAPT treatment as well as Wnt-3a treatment resulted in a downregulation 
of HES5 and GFAP mRNA levels, it arose the question, whether combined treatment is able 
to intensify the single effects. Therefore ReNcell VM cells were differentiated for up to 72 h 
under 5 µM DAPT and 100 ng/ml Wnt-3a treatment. mRNA levels of HES1, HES5, GFAP, 
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and MASH1 were compared to 5 µM DAPT treatment to illustrate the additive effect of  
Wnt-3a.  
Addition of Wnt-3a was able to induce the HES1 mRNA level after 2 h of treatment 
compared to DAPT alone. But after 6 h and 48 h, Wnt-3a addition led to a decrease of HES1 
mRNA while in other time points no significant regulation was detectable (Figure 15, A). 
Simultaneously, HES5 mRNA level was stronger downregulated by Wnt-3a in addition to its 
downregulation by DAPT alone (Figure 15, B). This regulation appeared already after 2 h up 
to 48 h of treatment except of 20 h and 30 h. Interestingly, double treatment with DAPT and 
Wnt-3a acted in the same time frame like Wnt-3a alone. Similar to HES5, GFAP mRNA level 
were decreased under double treatment and showed already after 3 h a significant and strong 
downregulation up to 72 h except of 12 h to 24 h (Figure 15, C). In contrast, double treatment 
resulted in no significant additive effect on MASH1 mRNA level. At 24 h time point 
however, Wnt-3a addition led to MASH1 upregulation by tendency. 
 
 
Figure 15: Modulation of Notch target genes in ReNcell VM cells by DAPT+Wnt-3a qRT-PCR of HES1 
(A), HES5 (B), GFAP (C) and MASH1 (D) in cells treated with DAPT+Wnt-3a. Data are normalized to DAPT 
treated cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
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Thus, Wnt-3a was clearly able to affect the HES5 and GFAP mRNA levels in addition to 
DAPT alone. Precisely, Wnt-3a was able to downregulate GFAP as well as HES5 in addition 
to DAPT, but did have no significant additional effect on HES1 and MASH1 mRNA levels. 
But it was a slight upregulation of MASH1 mRNA by tendency supposable. 
FACS analysis of 3 days differentiated cells positive for the neural marker HuC/D and Tuj1 
revealed no significant induction of positive cells under DAPT+Wnt-3a treatment compared 
to only DAPT treated cells (Figure 16, A and B), which fits well with the MASH1 mRNA 
analysis. Simultaneously, the inductive effect of DAPT treatment on ReNcell VM cells 
positive for neural markers HuC/D and Tuj1 (Figure 12, C and D) was verified for treated (but 
not transfected, like Figure 12) cells compared to DMSO treated control cells. S100β was not 
affected by DAPT or DAPT+Wnt-3a treatment (Figure 16, C). In contrast, GFAP was clearly 
decreased by DAPT compared to DMSO from 74 % to 58 % and especially by DAPT+ 
Wnt-3a (down to 40 %) compared to DMSO as well as DAPT treatment alone (Figure 16, D).  
 
 
Figure 16: Induction of Neurogenesis in ReNcell VM cells by DAPT+Wnt-3a treatment. Flow cytometric 
data showing percentages of DAPT and DAPT+Wnt-3atreated cells positive for HuC/D (A), Tuj1 (B), S100β 
(C) and GFAP (D) differentiated for 3 days in the presence of DAPT and DAPT+Wnt-3a or DMSO as control. 
Data are presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, *** 
p<0.001 compared to time point control. 
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In summary, only DAPT was able to increase cells positive for HuC/D and Tuj1 compared to 
DMSO. But only GFAP was significantly downregulated by DAPT compared to DMSO and 
by DAPT+Wnt-3a compared to DMSO as well as DAPT. 
Similar to the FACS data, immunocytochemistry cLSM-pictures (confocal laser scanning 
microscope) showed an increase in cells positive for Tuj1 when treated with Wnt-3a 
compared to HSA (Figure 17, A and B) and DAPT compared to DMSO (Figure 17, C and D). 
In addition, the amount of cells positive for GFAP decreased under DAPT and DAPT+Wnt-
3a treatment compared to DMSO treated cells (Figure 17, C, D and E). Moreover, under 
DAPT treatment a net like growth pattern was observable (Figure 17, D) which got more 
distinct by treatment with DAPT+Wnt-3a (Figure 17, E). This net like structure of these cells 
led to a thicker cell layer where more cells were grown over each other and did not build a 
monolayer anymore. Therefore it was not possibly to count the cells or nuclei. Interestingly, 
GFAP positive cells were only encountered in the inner part of the net like structure while 
Tuj1 positive cell branches were visibly across the whole surface.  
 
Figure 17: Induction of neurogenesis in ReNcell VM cells. Immunocytochemistry of cells positive for DAPI 
(blue), Tuj1 (green) and GFAP (red) differentiated for 3 days in the presence of Wnt-3a (B), DAPT (D) and 
DAPT+Wnt-3a (E) or HSA (A) and DMSO (C) as control. Representative pictures were acquired by cLSM in 
the center of Microscopy of the University of Rostock with help of Heiko Lemcke.  
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3.3.3 Time dependency of Wnt-3a/DAPT effects on neurogenesis 
As shown before, Wnt-3a, DAPT as well as DAPT+Wnt-3a were able to induce neurogenesis 
and to reduce GFAP, mRNA levels as well as amount of positive cells, compared to their 
controls. All substances were acting very fast but only Wnt-3a seemed to lose its effect after 
24 h of treatment but nevertheless it was able to upregulate neuronal markers after 3 days of 
differentiation. These data led to the question whether Wnt-3a and DAPT are able to induce 
neurogenesis even if they are not present during the whole differentiation period. Therefore, 
ReNcell VM cells were differentiated for 3 days and were treated only for 3 h, 6 h, 24 h, 48 h 
and 72 h. After treatment cells were washed and differentiated for up to 3 days without 
substances.  
After 24 h treatment with DAPT and DAPT+Wnt-3a treatment, Tuj1 showed the first 
induction of positive cells (Figure 18, A). Since the standard deviation was untypically high in 
some time points a clear distinction was difficult. But an increase in cells positive for Tuj1 in 
long compared to short substance-exposure was supposable. Interestingly, HuC/D was the 
only marker which was affected when treated for short time frames. It showed already after 
3 h of treatment an increase in positive cells when treated with Wnt-3a, DAPT or 
DAPT+Wnt-3a compared to HSA or DMSO (Figure 18, B). The amount of positive cells was 
only increasing if cells were treated longer with substances. Strikingly, no difference in 
HuC/D positive cells was detectable between 48 h of treatment compared to 72 h. Similar to 
Tuj1, GFAP was initially regulated after at least 24 h of treatment with DAPT+Wnt-3a 
compared to DMSO. Between 48 h and 72 h there were no clear differences visible under 
DAPT or DAPT+Wnt-3a treatment, only Wnt-3a compared to HSA treatment showed after 
72 h the first significant downregulation of GFAP positive cells (Figure 18, C). Surprisingly, 
S100β showed after 48 h a downregulation of positive cells by DAPT+Wnt-3a treatment 
compared to DMSO as well as DAPT. This is the only time that a significant regulation of 
S100β was detectable (Figure 18, D).  
In summary, HuC/D is a very early neuronal marker which is modifiable by treatments with 
short time frames. In contrast, Tuj1 and GFAP needed at least 24 h to be regulated by DAPT 
and DAPT+Wnt-3a, while Wnt-3a alone needed 72 h to modulate GFAP. The downregulation 
of S100β by DAPT+Wnt-3a was visible in all time points beginning from 24 h by tendency 
but it was only significant at 48 h.  
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Figure 18: Time dependency of ReNcell VM cell treatment. Flow cytometric data showing percentages of 
cells positive for Tuj1 (A), HuC/D (B), GFAP (C) and S100β (D) differentiated for 3 days in the presence of 
HSA, Wnt-3a, DMSO, DAPT and DAPT+Wnt-3a. Cells were treated at time point 0 h and were washed after 
3 h, 6 h, 24 h, 48 h or 72 h, respectively. Data are presented as means ± SEM from at least three independent 
experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
To further analyze the fast increase of HuC/D positive cells under DAPT and DAPT+Wnt-3a 
treatment, ReNcell VM cells were differentiated and treated for 1 day instead of 3 days. After 
just 1 day of differentiation a significant increase of HuC/D positive cells was visible when 
treated with DAPT compared to DMSO or treated with DAPT+Wnt-3a compared to DMSO 
as well as DAPT (Figure 19). In contrast, 1 day of differentiation was not sufficient to give 
rise to Tuj1 positive cells and no differences were observable for the marker GFAP and 
S100β (data not shown). 
This underlines that HuC/D is a very early marker of neurogenesis in ReNcell VM cells and is 
useful to predict early progenitor cell fate.  
 
Figure 19: HuC/D positive ReNcell VM cells after 24 h of differentiation under treatment. Flow cytometric 
data showing percentages of cells positive for HuC/D (A) differentiated for 1 day in the presence of HSA,  
Wnt-3a, DMSO, DAPT and DAPT+Wnt-3a. Data are presented as means ± SEM from at least three independent 
experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
Not only is the duration of treatment is important for the differentiation but also the point 
when the treatment starts. Taking this into account, ReNcell VM cells were treated after 18 h, 
24 h and 66 h of differentiation with HSA, Wnt-3a, DMSO, DAPT and DAPT+Wnt-3a until a 
total length of 72 h of differentiation.  
Interestingly, only DAPT+Wnt-3a were able to induce Tuj1 positive cells when treated after 
18 h of differentiation (Figure 20, A). Later in differentiation no regulation is detectable. 
HuC/D positive cells were able to be induced after 18 h and even after 24 h of differentiation 
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(Figure 20, B). In this case, the percentage of positive cells under Wnt-3a treatment was after 
18 h of differentiation as high as after treatment for full 72 h (Figure 18, B). In contrast, 
DAPT and DAPT+Wnt-3a treated cells were induced only up to 15 % instead of 40 % and 
28 % instead of 58 %. Thus, DAPT compared to Wnt-3a needed to act at the beginning of the 
differentiation to develop its whole potential. In contrast, no regulation of GFAP or S100β 
was observable in all time points (Figure 20, C and D).  
In summary, Wnt-3a as well as DAPT displayed a time frame where they were able to 
influence the differentiation of ReNcell VM cells. This time frame starts at the differentiation 
induction and seemed to end at 48 h after differentiation.  
 
 
Figure 20: Time dependency of ReNcell VM cell treatment. Flow cytometric data showing percentages of 
cells positive for Tuj1 (A) HuC/D (B), GFAP (C) and S100β (D) differentiated for 3 days in the presence of 
HSA, Wnt-3a, DMSO, DAPT and DAPT+Wnt-3a. Cells were treated at time point 18 h, 24 h, or 66 h after start 
of differentiation, respectively. Data are presented as means ± SEM from at least three independent experiments. 
*p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4 The mechanism behind the Wnt-3a effect 
Wnt-3a was shown before to modulate different pathways, e.g.Notch and BMP, depended on 
cell type and vicinity (Peignon et al., 2011). In addition, Hübner et al. (2010) showed that the 
activation of the Wnt pathway in ReNcell VM cells by Wnt-3a but also that overexpression of 
stabilized β-catenin could activate Wnt signaling as assessed by target gene analysis. 
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However, β-catenin overexpression was not sufficient to increase neuronal differentiation in 
ReNcell VM cells (Hübner et al., 2010). Moreover, it was not able to modulate Notch target 
genes HES1/HES5 or GFAP (Rayk Hübner, personal communication). These results 
suggested a mechanism resulting in increased neuronal differentiation which is independent of 
β-catenin and lead to the question: which other pathway(s) is/are involved in the Wnt-3a 
mediated modulation of HES1 and HES5, as well as downregulation of GFAP, which are 
accompanied by an increase in neuronal differentiation of ReNcell VM cells?  
To analyze the mechanism behind the Wnt-3a effect and the involved pathways, at first the 
Wnt pathway and its main proteins were tried to be excluded to be essential for the signalling. 
Afterwards the relevance of the Notch, BMP (Bone Morphogenetic Protein) and the 
JAK/STAT3 pathway was analyzed. Wnt ligands were already described to affect the Notch 
and BMP pathway, but STAT3 was only known to be modulated by HES1 and/or HES5 
(Kamakura et al., 2004). 
 
3.4.1 Analysis of the Wnt pathway dependency 
As described before, the effect of Wnt-3a on the Notch target genes and the differentiation of 
the ReNcell VM cells are independent of β-catenin (see 1.3). This leads to the question if the 
effect is only independent of β-catenin or independent of the whole β-catenin dependent Wnt 
pathway. In addition, a crosstalk between Wnt and Notch pathway was already described in 
1999 by Cooper and colleagues. They postulated that Fz/Dvl promotes activity of the Notch 
ligand Delta and inhibits Notch receptor activity in R3 Drosophila melanogaster eyes. In 
2009 Ribeiro et al. described that GSK3β phosphorylation of Notch2 inhibits transcription of 
the Notch target gene HES1. Furthermore, while Wnt signaling inhibits GSK3β, and since 
overexpression of Wnt-1 upregulates HES1, Espinosa et al. (2003) suggested that Notch 
phosphorylation by GSK3β regulates cross-talk between the Notch and Wnt pathways. This 
leads to the suggestion that Wnt-3a may modulate the Notch pathway in ReNcell VM cells via 
Wnt-pathway-proteins upstream of β-catenin. To answer these questions, the impact of 
upstream proteins like GSK3β, LRP6 and Frizzeld were analyzed. 
3.4.1.1 GSK3 dependency 
One of the main points of the Wnt pathway activation is the inhibition of GSK3 by Wnt-3a, 
where the exact mechanism is still under discussion (Metcalfe and Bienz, 2011). There are 
also small molecules available like SB216763 and IM12 which are able to specifically inhibit 
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GSK3 and therefore activating the β-catenin dependend Wnt pathway (Schmöle et al., 2010). 
IM12 was described before by Schmöle et al., 2010. If the Wnt-3a effect depends solely on 
GSK3 these small molecules would be able to mimic the effect.  
Treatment of cells with SB216763 significantly induced the mRNA level of Wnt target gene 
AXIN2 after 3 h and 6 h and after 12 h and 24 h by tendency (Figure 21, A) thus 
demonstrating GSK3 inhibition .While Wnt-3a was able to induce HES1 mRNA level (Figure 
14, A) SB216763 reduced it after 3 h, 8 h and 24 h (Figure 21, B). Interestingly, HES5 was 
induced after 6 h of treatment but reduced after 8 h and 24 h (Figure 21, C). However, GFAP 
was slightly reduced only after 24 h compared to control treated cells (Figure 21, D).  
In summary, SB216763 was able to induce the Wnt pathway as judged by increasing AXIN2 
mRNA level. HES1 was reduced and HES5 was slightly induced at an early time point but 
reduced in later time points, while GFAP was not affected until 24 h after treatment and was 
subsequently marginally reduced.  
 
 
Figure 21: Modulation of genes in ReNcell VM cells by GSK3 inhibition via SB216763. qRT-PCR of 
AXIN2 (A), HES1 (B),HES5 (C) and GFAP (D) in cells treated with SB216763. Data are normalized to DMSO 
treated cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
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As shown before, Wnt-3a was able to induce the neural marker HuC/D and Tuj1 and reduced 
the stem/glial marker GFAP but did not affect the glial marker S100β. To further analyze the 
impact of GSK3, 3 days differentiated ReNcell VM cells were stained for the mentioned 
markers.  
The amount of cells positive for the neural marker HuC/D and Tuj1 of IM12 or SB216763 
treated ReNcell VM cells was not significantly induced but slightly by tendency (Figure 22, A 
and B). Furthermore, there was no difference between the amount of cells positive for GFAP 
treated cells and control cells (Figure 22, D). Strikingly, SB216763 as well as IM12 were able 
to significantly reduce S100β positive cells (Figure 22, C).  
In conclusion, inhibition of GSK3 was not able to mimic the effect of Wnt-3a on 
differentiating ReNcell VM cells.  
 
 
Figure 22: Modulation of ReNcell VM cells by GSK3β inhibitors. Flow cytometric data showing percentages 
of IM12 and SB216763 treated cells positive for HuC/D (A), Tuj1 (B), S100β (C) and GFAP (D) differentiated 
for 3 days in the presence of IM12, SB216763 or DMSO as control. Data are presented as means ± SEM from at 
least three independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
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3.4.1.2 LRP5/6 dependency 
Low-density lipoprotein receptor-related proteins 5/6 are the best described co-receptors of 
the β-catenin dependent Wnt signaling pathway. They form receptor complexes with Frizzled 
and the ligand Wnt-3a. This interaction is able to be blocked by Dickkopf-related protein 1 as 
shown by Munji et al. (2011) in cortical intermediate progenitors. Therefore, Dkk-1 was used 
to analyze whether Wnt-LRP5/6 interaction would be required to influence HES gene 
regulation. If this effect is independent of LRP5/6, an inhibition by Dkk-1 would not inhibit 
Wnt-3a effects on HES gene expression and vice versa. The Wnt target gene AXIN2 was 
maximally increased in ReNcell VM cells upon 3 h of Wnt-3a treatment (Hübner et al., 2010). 
A concentration of 400 ng/ml of Dkk-1 was chosen, since this concentration appeared to 
efficiently inhibit the Wnt-3a induced AXIN2 upregulation and the increase of cytosolic β-
catenin compared to other concentrations (Kathleen Müller, 2012). Higher concentration 
failed to maximize the effect. Therefore, the cells were differentiated and, after pretreatment 
for 1 h with Dkk-1, treated with Wnt-3a (100 ng/ml) for additional 3 h.  
Wnt-3a treatment induced to a 20-fold increase of AXIN2 transcript levels while Dkk-1 was 
significantly able to inhibit this induction down to 7-fold (Figure 23). In addition, Wnt-3a 
decreased GFAP levels down to 0.7-fold as well as HES5 down to 0.8-fold, while HES1 was 
not significantly affected, but increased by tendency. Strikingly, Dkk-1 mediated inhibition of 
signaling did not affect the downregulating effect of Wnt-3a on HES5 and GFAP. In contrast, 
Wnt-3a +Dkk-1 treatment was able to significantly further downregulate HES5 compared to 
Wnt-3a treatment. 
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Figure 23: Modulation of genes in ReNcell VM cells by Dkk-1 (400 ng/ml). qRT-PCR of AXIN2, GFAP, 
HES1 and HES5 in cells treated for 3 h with 100 ng/ml Wnt-3a or Dkk-1+Wnt-3a. Data are normalized to HSA 
treated cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4.1.3 Frizzled dependency 
The Frizzled receptors are one part of the receptor complex which is required for the 
activation of the β-catenin dependent Wnt pathway, but also are involved in β-catenin 
independent Wnt pathways (Kikuchi et al., 2009). The secreted Frizzled related protein 1 
(sFRP1) is able to inhibit the interaction of Wnt-3a to its receptor Frizzled (Wawrzak et al., 
2007). 500 ng/ml was used to inhibit the Wnt-3a derived AXIN2 induction, where higher 
concentrations were not able to maximize the effect, 6 h of treatment was chosen due to the 
fact, that there was the best AXIN2 reduction detectable by sFRP1 (data not shown). Cells 
were differentiated and treated with sFRP1+Wnt-3a (100 ng/ml) for 6 h. 
Wnt-3a induced AXIN2 expression after 6 h of treatment up to 10-fold and this was 
significantly reduced by sFRP1 down to 5-fold (Figure 24). In addition, neither Wnt-3a nor 
sFRP1+Wnt-3a were able to significantly affect the mRNA level of GFAP and HES1 after 6 h 
of treatment, but both decreased GFAP and increased HES1 by tendency. Interestingly, the 
Wnt-3a evoked reduction of HES5 was not significantly affected by sFRP1 but was increased 
by tendency from 0.3-fold to 0.5-fold.  
In summary, sFRP1 was able to reduce the Wnt-3a induced upregulation of AXIN2 but did 
not significantly influence the modulation of GFAP, HES1 or HES5 mRNA levels.  
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Figure 24: Modulation of genes in ReNcell VM cells by sFRP1 (500 ng/ml). qRT-PCR of AXIN2, GFAP, 
HES1 and HES5 in cells treated for 6 h with Wnt-3a or sFRP1+Wnt-3a. Data are normalized to HSA treated 
cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4.2 Analysis of the Notch pathway dependency 
As described before, the effect of DAPT on ReNcell VM cells depends on the Notch 
intracellular domain 1 (NICD1). It was further analyzed whether Wnt-3a also depends on 
NICD1. Furthermore, HES1 as well as HES5 were overexpressed to show their relevance in 
the Wnt-3a effect on neuronal differentiation. 
 
3.4.2.1 Notch1 dependency 
To further analyze the impact of the Notch pathway, NICD1 overexpressing cells were treated 
with Wnt-3a.  
NICD1 overexpression reduced the amount of positive cells for the neural marker HuC/D and 
Tuj1 in control as well as in Wnt-3a treated cells (Figure 25, A and B). Interestingly, in 
control treated cells NICD1 overexpression lead to a slightly increase in GFAP positive cells 
compared to control transfected cells. As described above, DAPT was not able to increase 
NICD1 transfected cells positive for neural markers compared to DMSO treated cells. The 
increase of HuC/D positive cells treated with DAPT compared to control might be explained 
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by the fact that not all cells were transfected and the non-transfected-cells were still able to 
respond to DAPT.  
As long as NICD1 was overexpressed, neither DAPT nor Wnt-3a was able to increase 
neurogenesis as judged by Tuj1 positive cells. This led to the suggestion that the DAPT as 
well as Wnt-3a effect on neuronal differentiation depended on the NICD1. 
 
 
Figure 25: NICD1 overexpression in ReNcell VM cells. Flow cytometric data showing percentages of 
pCAGGS-NICD1 transfected cells positive for HuC/D (A), Tuj1 (B), and GFAP (C) differentiated for 3 days in 
the presence of Wnt-3a (100 ng/ml), DAPT (5 µM), or HSA, DMSO as control. Data are presented as means ± 
SEM from at least three independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point 
control. 
 
3.4.2.2 HES5 dependency 
The suggestion that DAPT as well as Wnt-3a effects on neuronal differentiation depend on 
the Notch intracellular domain 1 lead to the question which NICD1 target gene may be 
responsible for the observed effect. Because Kageyama et al. (2008) showed that NICD was 
not able to inhibit neurogenesis without HES1 and HES5. As shown above, NICD1 was able 
to increase HES5 (Figure 12, B). Therefore, HES5 was overexpressed in ReNcell VM cells to 
investigate if HES5 is able to reverse the effects of Wnt-3a and DAPT in the differentiating 
cells.  
HES5 overexpressing ReNcell VM cells were treated with HSA, Wnt-3a, DMSO, and DAPT 
and were compared to GFP transfected cells. Strikingly, overexpression of HES5 efficiently 
inhibited the differentiation of the cells. After 3 days of differentiation the cells displayed 
clearly proliferation morphology and not the typical neuron like morphology with long axons 
and small and defined cell bodies (Figure 26).  
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Figure 26: Overexpression of HES5 in ReNcell VM cells. Phase contrast of 3 days differentiated cells 
transfected with HES5 or GFP as control, respectively. Scale bar 100 µm. 
 
The overexpression of HES5 led to a decrease of Tuj1 as well as HuC/D positive cells 
compared to GFP transfected cells (Figure 27, A and B). In the case of the HuC/D positive 
cells, HES5 not only was able to inhibit the effect of Wnt-3a and DAPT, namly the induction 
of neurogenesis but also reversed this effect (Figure 27, B). Simultaneously, the amount of 
cells positive for Tuj1 under DAPT treatment was also reduced by HES5 overexpression 
(Figure 27, A). Interestingly, HES5 transfected cells positive for GFAP were increased 
compared to GFP transfected cells, but only under Wnt-3a treatment (Figure 27, C). The 
increase of HES5 transfected cells positive for GFAP was also not significant but visibly by 
tendency. The same was true for Tuj1 positive cells under Wnt-3a treatment; they were, in 
this experiment, not significantly increased by Wnt-3a compared to HSA as seen in 
experiments described above. Simultaneously, there were no differences detectable in cells 
positive for S100β (Figure 27, D). 
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Figure 27: HES5 overexpression in ReNcell VM cells. Flow cytometric data showing percentages of hHES5 
transfected cells positive for Tuj1 (A), HuC/D (B), GFAP (C) and S100β (D) differentiated for 3 days in the 
presence of Wnt-3a (100 ng/ml), DAPT (5 µM) or HSA, DMSO as control. Data are presented as means ± SEM 
from at least three independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
In addition, qRT-PCRs were performed to analyze the effects of HES5 on HES1, GFAP and 
MASH1. Overexpression of HES5 in ReNcell VM cells led to a strong, down to 0.1 fold, 
reduction of HES1 mRNA level already 24 h after transfection, which was the time point (0 h) 
of induction of differentiation, until 72 h of differentiation (Figure 28, A). The mRNA level of 
the proneural gene MASH1 was reduced after 0 h up to 72 h as well (Figure 28, C). 
Surprisingly, the level of GFAP mRNA was also reduced by HES5 overexpression at all time 
points (Figure 28, D). This seemed to be in contrast to the flow cytometric data, where the 
amount of GFAP positive cells was increased (Figure 27, C). Overexpression of HES5 was, in 
addition, clearly detectable by the up to 370-fold increase of HES5 mRNA (Figure 28, B) and 
in western blot analysis (Figure 10). 
In summary, HES5 was able to strongly reduce neuronal differentiation which was also 
accompanied by MASH1 mRNA reduction. Interestingly, HES5 was able to reduce HES1 
levels and strongly reduced GFAP mRNA level. 
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Figure 28: Modulation of genes in ReNcell VM cells by HES5 overexpression. qRT-PCR of HES1 (A), 
HES5 (B), MASH1 (C) and GFAP (D) in cells transfected with hHES5. Data are normalized to GFP transfected 
cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4.2.3 HES1 dependency 
As described above, NICD1 was able to induce HES5 and slightly reduce HES1 (Figure 12, 
B). In addition, it was shown that the effect of Wnt-3a and DAPT seemed to depend on 
NICD1 as well as HES5. This arose the question what impact HES1 may have on the 
differentiation of ReNcell VM cells and whether HES1 may be a mediator of the effects of 
Wnt-3a and DAPT. To answer this question, HES1 transfected cells were treated with HSA, 
Wnt-3a, DMSO and DAPT as control. GFP transfected cells served as control. 
In general, HES1 overexpression led to a significant reduction of Tuj1 as well as HuC/D 
positive cells compared to GFP control transfected cells (Figure 30, A and B). This reduction 
was not as strong as the reduction caused by HES5 transfected cells (see Figure 27). This fits 
well to the slight inhibition of the differentiation of ReNcell VM cells by HES1 compared to 
HES5 as judged by phase contrast microscopy (Figure 29).  
 
Results  68 
 
 
 
Figure 29: Overexpression of HES1 in ReNcell VM cells. Phase contrast of 3 days differentiated cells 
transfected with HES1 or GFP as control, respectively. Scale bar 100 µm. 
 
Interestingly, the number of HES1 transfected cells positive for HuC/D were still able to be 
induced by Wnt-3a as well as DAPT compared to control treated cells (Figure 30, B). Even if 
this induction was not as high as GFP control transfected cells, it led to the suggestion that the 
Wnt-3a and DAPT effect may be independent of HES1. Overexpression of HES1 in 
combination with Wnt-3a treatment led to a significant induction of GFAP positive cells 
compared to GFP transfected and Wnt-3a treated cells (Figure 30, C). In all other treatments, 
an induction was only visible by tendency. HES1, furthermore, significantly induced the 
amount of S100β positive cells in HSA control treated cells (Figure 30, D). This effect was 
not detectable in other treatments.  
 
Figure 30: HES1 overexpression in ReNcell VM cells. Flow cytometric data showing percentages of hHES1 
transfected cells positive for Tuj1 (A), HuC/D (B), GFAP (C) and S100β (D) differentiated for 3 days in the 
presence of Wnt-3a, DAPT or HSA, DMSO as control. Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
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HES1 overexpression led to a strong increase in HES1 (mRNA level: Figure 31, A; protein: 
Figure 9) and to a reduction of HES5 (Figure 31, B). Despite the fact that HES1 was still 
increased after 72 h the reduction of HES5 was lost after 72 h of differentiation. MASH1 
mRNA level was also decreased by HES1 overexpression but was lost after 72 h of 
differentiation (Figure 31, C). Similar to that, GFAP levels were decreased up to 24 h of 
differentiation but at the level of control treated cells after 72 h (Figure 31, D).  
In summary, HES1 reduced HES5, GFAP and MASH1 transcript levels but after 72 h they 
were no longer regulated by HES1. HES1 furthermore reduced the neuronal differentiation 
and increased S100β positive cells in HSA control treated cells. However, its effects on 
ReNcell VM differentiation were weaker than those observed in HES5 overexpression 
experiments.  
 
 
Figure 31: Modulation of genes in ReNcell VM cells by HES1 overexpression. qRT-PCR of HES1 (A), 
HES5 (B), MASH1 (C) and GFAP (D) in cells transfected with hHES1. Data are normalized to GFP transfected 
cells (time point control, indicated as black line). Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4.3 Analysis of the BMP pathway dependency 
The bone morphogenetic protein pathway is not only known to regulate bone formation, but 
also plays a major role in diverse diseases, during embryonic development and in adult tissue 
homeostasis (Bandyopadhyay et al., 2013). Furthermore, BMP is able to modulate the 
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differentiation of neural stem cells (Song et al., 2011). Nakashima et al. (2005) described an 
inhibition of the BMP target gene ID1 by Wnt-3a treatment in C2C12 cells. In addition, it was 
shown that BMP2 enhance Notch induced transcriptional activation of HES5 in mouse 
neuroepithelial cells (Takizawa et al., 2003). This led to the suggestion that Wnt-3a may be 
able to inhibit the BMP pathway in ReNcell VM cells, thereby potentially regulating the 
differentiation independently of β-catenin.  
 
3.4.3.1 Effect of Wnt-3a on the BMP pathway 
The best described target genes of the BMP pathway are the bHLH transcription factors 
inhibitor of differentiation 1 and 3 (ID1 and ID3; Obayashi et al., 2009). To verify a BMP 
inhibition by Wnt-3a, these target genes were analyzed.  
Wnt-3a treatment of ReNcell VM cells led to a significant reduction of ID1 as well ID3 after 
3 h, 6 h and 8 h (Figure 32, A and B). The reduction was lost after 24 h of treatment on ID1, 
but ID3 was slightly induced after 24 h of Wnt-3a treatment.  
In summary, Wnt-3a was able to reduce the BMP target genes ID1 and ID3 for up to 8 h 
significantly but lost its effect after 24 h of treatment. These data indicated that BMP 
signaling was active in these cells and Wnt-3a was able to inhibit this pathway. 
 
 
Figure 32: Modulation of BMP target genes in ReNcell VM cells by Wnt-3a. qRT-PCR of ID1 (A) and ID3 
(B), in cells treated with Wnt-3a. Data are normalized to HSA treated cells (time point control, indicated as black 
line). Data are presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, *** 
p<0.001 compared to time point control. 
 
3.4.3.2 Inhibition of the BMP pathway 
Due to the fact that Wnt-3a was at least able to reduce ID1 and ID3 up to 8 h after induction 
of differentiation, it was aimed to mimic the Wnt-3a effect by inhibiting the BMP pathway 
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with known inhibitors. In addition, HES5 and GFAP were analyzed to check if the inhibition 
of BMP is able to modulate Notch target genes in the same manner as Wnt-3a. 
There are three well described substances to inhibit the BMP pathway. Noggin binds the 
ligand BMP2, 4 and 7 and therefore inhibits the SMAD1, 5, 8 and MAPK p38 (Yu et al., 
2008). Dorsomorphin inhibits BMP4 induced signaling and does not affect MAPK p38 (Yu et 
al., 2008). SB431542 inhibits the TGF-β signaling pathway and therefore SMAD2 and 3 
(Inman and Hill, 2002).  
 
Noggin 
Noggin (500 ng/ml; Yu et al., 2008) was able to reduce the amount of ID1 mRNA levels 
already after 3 h down to 0,2-fold und up to 24 h of treatment (Figure 33, A). ID3 was also 
reduced however less strongly down to 0,4-fold after 3 h of treatment but similarly up to 24 h 
(Figure 33, B). Interestingly, Noggin reduced HES5 after 3 h of treatment down to 0,8-fold 
afterwards it increased HES5 over to 2-fold after 8 h and 24 h of treatment (Figure 33, C). 
GFAP instead was only faintly downregulated by Noggin after 8 h (Figure 33, D) but no 
regulation was detectable in all other time points. To clarify if Noggin was able to modulate 
the cell fate of ReNcell VM cells the amount of cells positive for the markers Tuj1, HuC/D, 
GFAP and S100β was analyzed. Noggin was not able to increase neurogenesis like Wnt-3a; 
instead it significantly decreased the amount of cells positive for the neural marker HuC/D 
(Figure 33, E). Simultaneously, the marker Tuj1 was reduced by Noggin treatment only by 
tendency (Figure 33, F) and S100β and GFAP were not affected (Figure 33, G and H).  
 
Figure 33: Modulation of ReNcell VM cells by Noggin. A-D: qRT-PCR of ID1 (A), ID3 (B),HES5 (C) and 
GFAP (D) in cells treated with Noggin. Data are normalized to HSA treated cells (time point control, indicated 
as black line). E-H: Flow cytometric data showing percentages of treated cells positive for HuC/D (E), Tuj1 (F), 
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S100β (G) and GFAP (H) differentiated for 3 days in the presence of Noggin or HSA as control. Data are 
presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, *** p<0.001 
compared to time point control. 
 
Dorsomorphin alias Compound C 
Dorsomorphin (1 µM; Yu et al., 2008) was able to reduce ID1 in all analyzed time points to 
0,4-fold (3 h of treatment) and to 0,7-fold at 8 h of treatment (Figure 34, A). In comparison, 
ID3 was similar down regulated after 3 h and 6 h of treatment but Dorsomorphin lost its 
impact on ID3 after 8 h and 24 h (Figure 34, B). Interestingly, neither HES5 nor GFAP was 
affected by Dorsomorphin treatment (Figure 34, C and D). But there was a significant 
reduction of HuC/D was well as Tuj1 positive cells under Dorsomorphin treatment (Figure 
34, E and F). The numbers of cells positive for the marker S100β and GFAP were not affected 
(Figure 34, G and H). 
 
 
Figure 34: Modulation of ReNcell VM cells by Dorsomorphin. A-D: qRT-PCR of ID1 (A), ID3 (B), HES5 
(C) and GFAP (D) in cells treated with Dorsomorphin. Data are normalized to DMSO treated cells (time point 
control, indicated as black line). E-H: Flow cytometric data showing percentages of treated cells positive for 
HuC/D (E), Tuj1 (F), S100β (G) and GFAP (H) differentiated for 3 days in the presence of Dorsomorphin or 
DMSO as control. Data are presented as means ± SEM from at least three independent experiments. *p<0.05, 
**p<0.01, *** p<0.001 compared to time point control. 
 
SB431542 
The impact of SB431542 on ReNcell VM cells was analyzed by FACS, to investigate the 
main effect: the modulation of differentiation. SB431542 slightly reduced the amount of cells 
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positive for HuC/D and Tuj1 by tendency (Figure 35, A and B) but did not affect S100β or 
GFAP (Figure 35, C and D).  
In summary, Wnt-3a as well as Noggin and Dorsomorphin were able to inhibit the BMP 
pathway alike. But the inhibition pattern of Wnt-3a and Dorsomorphin, with the loss of ID3 
inhibition after 24 h, was equal. Nevertheless, neither Noggin nor Dorsomorphin nor 
SB431542 were able to increase neurogenesis like Wnt-3a or reduce GFAP positive cells. But 
interestingly, Noggin as well as Dorsomorphin was able to reduce cells positive for HuC/D. 
 
 
Figure 35: Modulation of ReNcell VM cells by SB431542. Flow cytometric data showing percentages of 
SB431542 treated cells positive for HuC/D (A), Tuj1 (B), S100β (C) and GFAP (D) differentiated for 3 days in 
the presence of SB431542 or DMSO as control. Data are presented as means ± SEM from at least three 
independent experiments. *p<0.05, **p<0.01, *** p<0.001 compared to time point control. 
 
3.4.4 Analysis of the JAK/STAT3 pathway dependency 
As described above, one of the effects of Wnt-3a and DAPT was the modulation of the 
neuronal differentiation and GFAP positive cells in ReNcell VM cells. The neuronal 
differentiation and GFAP are both regulated by transcription factors like HES5. Another well 
described transcription factor, which regulates GFAP together with HES5 (Nakashima et al., 
1999, Kamakura et al., 2004) and therefore is able to regulate neurogenesis, is the signal 
transducer and activator of transcription 3 (STAT3). In 2006 Hao and colleagues 
demonstrated that Wnt-3a was able to upregulate STAT3 in mouse embryonic stem cells. 
Furthermore, Fragoso et al. (2012) identified Wnt-3a as an activator of STAT3, where an 
upregulation of phosphorylated STAT3 at Tyr 705, in the retinal pigment epithelium ARPE-
19 cell line was abserved. This led to the suggestion that Wnt-3a could act through the 
activation of pSTAT3. 
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3.4.4.1 Activation and inhibition of pSTAT3 in ReNcell VM cells 
The first step to show an active STAT3 signaling pathway in ReNcell VM cells was to detect 
both the total STAT3 and the active form of STAT3, pSTAT3; at TYR705. Due to the fact, 
that STAT3 is a transcription factor which forms dimers and subsequently translocates into 
the nucleus (Darnell et al., 1994) the second step was to detect nuclear pSTAT3. This 
activation and translocation can be activated with the small molecule AICAR (Zang et al., 
2008) and be inhibited by Jak-Inhibitor-1 (Pedranzini et al., 2006). 
In total cell lysates of differentiating ReNcell VM cells was a strong STAT3 as well as a faint 
pSTAT3 signal detectable (Figure 36, A). Furthermore, a pSTAT3 signal was slightly 
inducible by AICAR while STAT3 was not affected. Simultaneously, a modulation of STAT3 
or pSTAT3 using the Jak-Inhibitor-1 was not detectable in total cell lysates (Figure 36, A). 
Therefore, nuclear levels of pSTAT3 and STAT3 were analyzed. There were no differences 
detectable in STAT3 levels (data not shown). But after 30 min of AICAR treatment was an 
increase of pSTAT3 detectable (Figure 36, B) while Jak-Inhibitor-1 decreased the amount of 
pSTAT3 by tendency.  
 
 
Figure 36: pSTAT3 and STAT3 in ReNcell VM cells. Western blot analysis of pSTAT3 and STAT3 in 
ReNcell VM cells in differentiation A: Western blot analysis of total protein lysates under 30 min H2O, AICAR, 
DMSO or Jak-Inhibitor-1 (Jak-I-1) treatment. B: Quantification of western blot analysis of nuclear pSTAT3 in 
cells treated for 30 min with H2O, AICAR, DMSO or Jak-Inhibitor-1 (Jak-I-1). Data are normalized to Lamin 
A/C (control set to 100 %). Data are presented as means ± SEM from three independent experiments. 
 
STAT3 together with HES5 is able to induce GFAP and inhibit neurogenesis in rat and mouse 
NSCs (Gu et al., 2005, Cao et al., 2010). This led to the question, what effect a treatment with 
AICAR and Jak-Inhibitor-1 may have on differentiating ReNcell VM cells.  
Strikingly, AICAR reduced the amount of cells positive for the neuronal marker HuC/D 
(Figure 38, A) and Tuj1 (Figure 38, B) drastically from 7 % of control cells, down to less than 
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1 %. Simultaneously, GFAP positive cells increased from 75 % up to 90 % (Figure 38, D), 
while S100β was not affected (Figure 38, C). Interestingly, treatment with Jak-Inhibitor-1 
resulted in no significant changes in the amount of cells positive for the analyzed markers, 
however neuronal markers were reduced by tendency (Figure 38, A to D). Phase contrast 
microscopy analysis revealed undifferentiated cells as assessed by cell morphology of 
ReNcell VM cells compared to control cells which fits well with the observed reduction of 
neuronal markers (Figure 37). In contrast, cells treated with AICAR revealed no differences in 
their morphology compared to control cells (data not shown). 
 
 
Figure 37: Treatment of ReNcell VM cells with Jak-Inhibitor-1 (Jak-I-1). Phase contrast of 3 days 
differentiated cells treated with 4 µM Jak-Inhibitor-1 or DMSO as control, respectively. Scale bar 100 µm. 
 
 
Figure 38: Modulation of ReNcell VM cells by AICAR and Jak-Inhibitor-1. Flow cytometric data showing 
percentages of AICAR or Jak-Inhibitor-1 treated cells positive for HuC/D (A), Tuj1 (B), S100β (C) and GFAP 
(D) differentiated for 3 days in the presence of AICAR, Jak-Inhibitor or H2O or DMSO as control. Data are 
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presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001 
compared to time point control. 
 
3.4.4.2 Does the Wnt or Notch pathway modulate pSTAT3? 
The phosphorylation and translocation of transcription factors is fast and delicate. The 
analyzed time point was chosen by the fact that after 6 h Wnt-3a as well as DAPT were able 
to modulate GFAP levels. Analysis of the pSTAT3 level in nuclear cell extracts of ReNcell 
VM cells treated with Wnt-3a detected no significant changes compared to control cells 
(Figure 39). Treatment with DAPT instead led to a significant decrease of pSTAT3 compared 
to DMSO from 100 % down to 32 %. A similar downregulation was observable by treatment 
with DAPT+Wnt-3a (Figure 39). 
 
 
Figure 39: Modulation of pSTAT3 by Wnt-3a and DAPT. Western blots of nuclear pSTAT3 in cells treated 
for 6 h with HSA, Wnt-3a, DMSO, DAPT or DAPT+Wnt-3a were quantified. Data are normalized to Lamin A/C 
(HSA and DMSO control set to 100 %). Data are presented as means ± SEM from three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001 compared to time point control. 
 
Since DAPT was able to reduce pSTAT3, but Wnt-3a had no effect and AICAR was able to 
induce pSTAT3, it was analyzed whether AICAR was able to rescue the effect of DAPT on 
neurogenesis.  
ReNcell VM cells were treated with DAPT and DAPT+AICAR for 3 days of differentiation. 
Afterwards, the amount of positive cells for the marker HuC/D, Tuj1, GFAP, and S100β was 
analyzed. Interestingly, AICAR was able to rescue the neuronal induction of DAPT. It 
reduced the amount of cells positive for HuC/D from 33 % down to 3 % (Figure 40, A) and 
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the Tuj1 positive cells from 20 % down to 1 % (Figure 40, B). Simultaneously, AICAR in 
combination with DAPT increased the amount of cells positive for S100β compared to DAPT 
alone (Figure 40, C). In addition, AICAR rescued the effect of DAPT on GFAP positive cells 
and increased the amount of positive cells up to 98 % from 70 % of DAPT or 85 % of DMSO 
treated cells, respectively (Figure 40, D).  
In summary, DAPT was able to reduce nuclear pSTAT3 levels while Wnt-3a had no effect on 
pSTAT3 levels. Furthermore, AICAR was able to effectively inhibit the effect of DAPT on 
neuronal differentiation and on the numbers of cells positive for GFAP.  
 
Figure 40: Modulation of ReNcell VM cells by AICAR and DAPT. Flow cytometric data showing 
percentages of treated cells positive for HuC/D (A), Tuj1 (B), S100β (C) and GFAP (D) differentiated for 3 days 
in the presence of AICAR+DAPT or H2O or DMSO as control. Data are presented as means ± SEM from at least 
three independent experiments. *p<0.05, **p<0.01, ***p<0.001 compared to time point control. 
 
3.5 Induced pluripotent stem cell derived neural progenitor cells (iPS-
NPCs) 
Signaling pathways are known to have different outcomes depending on the cellular context 
and time dependency. To verify the results observed using ReNcell VM cells and to clarify 
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that it is not a cell type depending phenomenon, another cell model was used. This model is 
based on neural progenitor cells (NPCs) which were derived from induced pluripotent stem 
cells (iPSC). These cells do express the same neural markers like ReNcell VM cells, Nestin 
and SOX2 (Trilck et al., 2013), and are able to differentiate into neuronal cells. Therefore, this 
cell line was ideal to verify the results obtained using the human neural progenitor cell line 
ReNcell VM.  
 
3.5.1 The Notch pathway in iPS-NPCs 
To demonstrate active Notch pathway in iPS-NPCs, DAPT was used to inhibit the Notch 
pathway. Similar to the ReNcell VM cell treatment, iPS-NPCs were treated once after 
induction of differentiation with 5 µM DAPT and HES1/HES5 mRNA levels were analyzed 
by qRT-PCR after 3 h, 6 h and 24 h. These time points were chosen because the first 24 h of 
differentiation seemed to be most important for the cell fate at least in ReNcell VM cells. 
DAPT was able to reduce the HES1 (Figure 41, A) as well as the HES5 (Figure 41, B) mRNA 
levels. Strikingly, DAPT was able to reduce HES5 obviously more potent than HES1 levels, 
which was also observable in ReNcell VM cells (Figure 11). In the analyzed time points in 
NPCs no MASH1 or GFAP mRNA levels were detectable.  
 
 
Figure 41: Inhibition of the Notch pathway in iPS-NPCs. qRT-PCR of HES1 (A) and HES5 (B), in cells 
treated with DAPT. Data are normalized to DMSO treated cells (time point control, indicated as black line). Data 
are presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001 
compared to time point control. 
 
3.5.2 The effect of Wnt-3a in differentiating iPS-NPCs 
As described before AXIN2 is one of the main target genes of the Wnt signaling pathway, 
therefore it was used to confirm the activation of the Wnt pathway in NPCs upon Wnt-3a 
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treatment. Furthermore, the effect of Wnt-3a on the Notch target genes HES1 and HES5 was 
analyzed. 
Wnt-3a was able to significantly increase AXIN2 in iPS-NPCs (Figure 42, A) as well as in 
ReNcell VM cells (Hübner et al., 2010). Likewise it induced HES1 mRNA level after 3 h and 
6 h (Figure 42, B) while HES5 levels were decreased after 6 h of treatment (Figure 42, C). 
Notably, HES1 induction was, compared to ReNcell VM cells, remarkably stronger and HES5 
downregulation less prominent. Regrettably the standard deviations in some time points were 
very high. In addition, Wnt-3a treatment led to an increase of the active form of β-catenin 
(non-phosphorylated at SER33/37/THR41) in total cell lysates analyzed via western blot 
(Figure 42, D). Thus, Wnt-3a was able to induce the β-catenin dependent signaling pathway, 
which led to an increase of active β-catenin and afterwards an induction of AXIN2. 
In summary, Wnt-3a was able to activate the β-catenin dependent Wnt pathway and induced 
HES1 and reduced HES5 mRNA levels after 6 h of treatment. 
 
 
Figure 42: Activation of the Wnt pathway and modulation of Notch target genes by Wnt-3a in iPS-NPCs. 
qRT-PCR of AXIN2 (A), HES1 (B) and HES5 (C) in cells treated with Wnt-3a (100 ng/ml). Data are 
normalized to HSA treated cells (time point control, indicated as black line). Data are presented as means ± SEM 
from at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001 compared to time point control. D: 
Western blot analysis of active non-phospho-β-catenin (n-p-β-catenin) under 6 h of Wnt-3a treatment. 
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3.5.3 The Wnt-3a and DAPT effect in the differentiation of iPS-NPCs 
To verify the ReNcell VM cell results, iPS-NPCs were treated in combination with  
Wnt-3a plus DAPT and were compared to DAPT alone to illustrate the additive effect of Wnt-
3a even to DAPT. Therefore the cells were treated once at the induction of differentiation 
with substances and the medium was changed every 48 h. In addition, the effects of Wnt-3a 
and DAPT treatment on the cell fate of iPS-NSCs were analyzed by detecting cells positive 
for the neuronal marker HuC/D, the mature glial marker S100β and the stem cell/glial marker 
GFAP. In the case of iPS-NPCs, GFAP has to be seen as a glial marker, in contrast to ReNcell 
VM cells, due to the fact that neither GFAP positive cells were detectable nor GFAP mRNA 
levels via qRT-PCR in proliferating cells (data not shown).  
As described before, HES1 was reduced upon DAPT treatment, but could be induced by Wnt-
3a+DAPT compared to DAPT alone after 3 h and 6 h of treatment (Figure 43, A). There was 
no Wnt-3a+DAPT induced regulation detectable after 24 h of treatment compared to DAPT 
alone, which was the same pattern as with Wnt-3a treatment alone (Figure 42, B). The double 
treatment with Wnt-3a+DAPT compared to DAPT alone had its most prominent effect on 
HES5 mRNA level after 6 h of treatment (Figure 43, B). Which was the same time point were 
Wnt-3a alone was able to reduce HES5 most of all. Interestingly, Wnt-3a only in combination 
with DAPT was able to reduce HES5 after 3 h and 24 h significantly compared to DAPT 
single treatment, while Wnt-3a alone was not able to reduce it compared to HSA (Figure 42, 
C). DAPT as well as Wnt-3a+DAPT were able to significantly reduce the amount of cells 
positive for the glial marker GFAP compared to DMSO (Figure 43, E). But the effect of 
DAPT and Wnt-3a+DAPT was most prominent in S100β positive cells (Figure 43, D). S100β 
was significantly reduced by Wnt-3a+DAPT down to 20 % compared to DAPT treated cells 
(30 %) or DMSO treated cells (47 %). A significant reduction of S100β upon Wnt-3a 
treatment was not detectable but a tendency was observable. Surprisingly, there were no 
differences of HuC/D positive cells detectable (Figure 43, E). 
In summary, Wnt-3a alone was not able to significantly modulate the fate of differentiating 
iPS-NPCs. But Wnt-3a+DAPT induced HES1 while HES5 was reduced compared to DAPT. 
In addition the double treatment was able to reduce the glial marker GFAP and S100β 
significantly compared to DMSO; whereas the already high amount of HuC/D positive cells 
was not changed. 
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Figure 43: Modulation of genes in iPS-NPCs. A-B: qRT-PCR of HES1 (A) and HES5 (B) in cells treated with 
DAPT+Wnt-3a. Data are normalized to DAPT treated cells (time point control, indicated as black line). C-E: 
Flow cytometric data showing percentages of treated cells positive for GFAP (C), S100β (D) and HuC/D (E) 
differentiated for 18 days in the presence of Wnt-3a, DAPT, DAPT+Wnt-3a or DMSO or HSA as control. Data 
are presented as means ± SEM from at least three independent experiments. *p<0.05, **p<0.01, ***p<0.001 
compared to time point control. 
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4 Discussion 
The most challenging diseases of humankind are the neurodegenerative diseases, since 
degeneration of neurons is irreversible and often lethal. Currently, we are not able to cure 
diseases like stroke or spinal cord injuries. A promising approach is the stem cell therapy. But 
at the moment there is, due to the fragmentary knowledge of differentiation of human neural 
stem and progenitor cells, no successful therapy availably (Martino and Pluchino, 2006).  
Differentiation of NPCs is controlled by a multitude of different pathways and their crosstalk, 
which regulates the neurogenesis as well as gliogenesis. Understanding these mechanisms 
will definitely provide the basis for directing differentiation of human NPCs for clinical 
applications. However, most of the knowledge is based on murine models and derived cell 
systems. Therefore, the cells of choice for identifying the pathways underlying neuronal 
differentiation are human neural progenitor cells like ReNcell VM cells, which have two 
defining properties: self-renewal and multipotentiality. These cells have the ability to 
differentiate into multiple neuronal cell types. ReNcell VM cells are a v-myc retrovirally 
immortalized human cell line and were derived from the ventral midbrain of a 10-week old 
male fetus (Donato et al., 2007). This cell line is able to differentiate after 3 days into S100β 
positive astrocytes and into HuC/D and Tuj1 positive neurons. Furthermore, proliferating cells 
express the neuronal marker Nestin and SOX2 as well as GFAP. 
The glial fibrillary acidic protein (GFAP) belongs to the intermediate filaments which are 
regulated developmentally and tissue-specific. It was mainly described as a marker protein for 
mature astrocytes (Gomes et al., 1999). However, recent findings reveal GFAP, in addition, as 
a marker for neural stem cells. For example Garcia et al., 2004 clearly showed that GFAP-
expressing progenitors are the principle source of constitutive neurogenesis in adult mouse 
forebrain. Furthermore, GFAP gene deletion seems not to have a distinct effect on 
neurogenesis or gliogenesis in mice (Gomi et al., 1995, Pekny et al., 1995). In the here used 
ReNcell VM cells GFAP is already expressed in proliferation and therefore cannot 
exclusively be seen as a mature astroglial marker. On this account GFAP was used as a 
marker for neural stem and progenitor cells.  
 
4.1 Generation of pCAGGS-hHES vectors 
The generation of pCAGGS-hHES vectors was successful, but due to the fact that at the 
beginning of this work the hHES proteins were not detectable in western blot analysis, it was 
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tried to add a HA-tag to the hHESs to facilitate detection. At first, expression vectors with an 
N-terminal tag were produced, because Kamakura et al. (2004) were able to overexpress N-
terminal tagged GST-HES fusion proteins in mouse E13 neuroepithelia cells. Afterwards, 
good working antibodies were obtained and the protein levels were again analyzed by western 
blot, but HA-hHES failed to be higher expressed than non-tagged vectors in ReNcell VM 
cells. While pCAGGS-HA-hHES5 was able to verify the protein size of hHES5 (Figure 49), 
hHES1 failed to be expressed using pCAGGS-HA-hHES1 (Figure 48). It is possible that the 
HA-tag inhibits the correct HES1 folding subsequently inducing its rapid degradation and 
therefore was not visible in western blot analysis.  
 
4.2 The Notch pathway in ReNcell VM cells 
To activate the Notch pathway the Notch transmembrane receptor has to be cleaved at two 
different sites. One is located at the outside of the membrane and releases the Notch 
extracellular domain (S2-cleavage) and the second is located at the inside of the membrane 
(S3-cleavage), which releases the Notch intracellular domain (NICD). This NICD can 
translocate to the nucleus and induce the transcription of the target genes like HES1 and 
HES5. There are 4 described Notch receptors in mammals and each release a different 
intracellular domain (1-4), in addition, NICDs are acting context depended (Bay, 2006). In 
human esophageal keratinocytes it was indicated, that NICD1 siRNA is able to downregulate 
HES5 mRNA levels (Ohashi et al., 2010). While Breunig et al. (2007) were able to classify 
NICD1 as an important Notch intracellular domain in GFAP positive mouse hippocampal 
cells, there is no such classification for human neural progenitor cells.  
Detection of the Notch intracellular domain 1 in differentiating ReNcell VM cells via western 
blot (Figure 11, B) suggested a regulatory role for NICD1 in human neural progenitor cells. 
This suggestion was supported by the activation as well as inhibition of NICD1 and its effect 
on neurogenesis. Precisely, NICD1 overexpression significantly reduced the amount of cells 
positive for neuronal markers (HuC/D and Tuj1; Figure 12, C and D). In contrast, the known 
Notch inhibitor DAPT increased the amount of cells positive for neuronal markers and 
decreased the amount of GFAP positive cells (Figure 12). Reduction of Notch target genes 
HES1/HES5 upon pharmacological inhibition of Notch signaling using DAPT (Figure 11) 
revealed that Notch signaling is active in ReNcell VM cells and controls neuronal 
differentiation. This was described before in other cell systems like hESC-derived NESs by 
Woo et al. (2009) and Borghese et al. (2010). 
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DAPT is a small molecule which is able to inhibit a variety of γ-secretases. Therefore, it 
inhibits not only the release of the Notch intracellular domain but also affects other proteins, 
which leads to multifarious ramifications. On that account, a rescue experiment verified the 
specific Notch depended effect. In this experiment the induction of neurogenesis by DAPT 
was rescued by overexpression of NICD1 (Figure 12). Simultaneously, the reduction of 
GFAP positive cells by DAPT was also rescued by NICD1 overexpression. Over all, DAPT 
reduced the mRNA level of the Notch target genes HES1 and HES5 significantly. 
Interestingly, HES5 was stronger affected than HES1 (Figure 11). This phenomenon has been 
shown before by Nelson et al. (2007) in chicken E4.5 retinal explants, where DAPT reduced 
HES5 levels (15-fold) more than HES1 levels (2-fold). Furthermore, Hartl et al. (2008) 
revealed that in mouse E13.5 (peak of neurogenesis) Notch1 protein and ICD were 
downregulated in the same magnitude like HES5, while HES1 was upregulated. In contrast, 
the activation of the Notch pathway by overexpression of NICD1 led not only to an augment 
of NICD1 but also induced the expression of HES5 while HES1 was decreased (Figure 12). 
This demonstrates a clear regulation of HES5 transcript levels by NICD1, but arises the 
question if NICD1 alone regulates HES1. A similar observation was made by Haupt et al. 
(2012), where the introduction of NICD1 into mouse and human neural stem cells resulted in 
a higher increase of HES5 than HES1. In addition, it was shown before that HES1 is not 
solely regulated by Notch (Kageyama et al., 2008). Moreover it is able to be modulated by 
other pathways (for example Shh; Wall et al., 2009) and by basic helix loop helix 
transcription factors, for example HES5 or itself (Takebayashi et al., 1994, Kageyama et al., 
2009). In contrast, Wu et al., 2002 showed a downregulation of HES5 by HES1 
overexpression in rat E14.5 spinal cord cells, which underlines a bilateral interaction.  
This work shows that NICD1 and DAPT, and therefore Notch, not only regulate the target 
genes HES1 and HES5 but also the GFAP and the proneural gene MASH1 (ASCL1; Figure 
11 and Figure 12). In addition, a clear downregulation of GFAP, on mRNA level as well as in 
FACS analysis, by DAPT and the rescue of the protein level by NICD1 overexpression were 
observed. Strikingly, the regulation of HES1 as well as HES5 by DAPT is very fast, within 
2 h, while GFAP is significantly inhibited not until 12 h (Figure 11). This suggests a direct 
regulation of HES but not a direct regulation of GFAP. The temporal delay suspects a direct 
regulation of HES, which in turn leads to a regulation of GFAP by HES. This assumption was 
confirmed in E14.5 rat glial restricted precursors by Wu et al. (2002) and in primary mouse 
neuroepithelial cells by Kamakura et al. (2004) as well as in mouse mesencephalic neural 
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crest cells by Ijuin et al. (2008). In contrast, Ge et al. (2002) professed a direct regulation of 
GFAP by CSL (RBP-J; CBF1/Su(H)/Lag-1) in rat cortical NPCs, but simultaneously 
predicted a cell context dependent mechanism of GFAP regulation. So it is possible, that 
Notch can activate GFAP by a direct binding of CSL to the GFAP promoter in rat cortical 
NPCs but not directly in human fetal ventral midbrain derived ReNcell VM cells.  
There is a variety of proneural genes in neural progenitors known to be negatively regulated 
by HES, like MASH1 (ASCL1), Neurogenin 1, and Neurogenin 2. These genes are known to 
drive NPCs to a neuronal differentiation (Castella et al., 1999, Kageyama et al., 2009). In 
ReNcell VM cells only MASH1 mRNA level was able to be detected via qRT-PCR, 
Neurogenin 1 and 2 levels could not be quantified due to very low mRNA levels (data not 
shown). The time delay between MASH1 regulation and the start of DAPT treatment (6 h; 
Figure 11) suggests an indirect regulation of MASH1 by HES. Precisely, HES1 and HES5 
were described to inhibit MASH1 function by competitively binding to its heterodimeric 
bHLH partners E12 and E47 (Nakashima et al., 2001). In contrast, Kageyama et al. (2008) 
reckoned a direct binding of HES factors to MASH1, which leads to heterodimers who were 
not able to bind DNA. In both ways a reduction of HES leads to an augment of free and 
therefore active MASH1 which in turn can drive NPCs in a neuronal differentiation. 
 
4.3 The effect of Wnt-3a treatment and Notch inhibition in the 
differentiation of ReNcell VM cells 
Wnt-3a was previously known as a classical “canonical” (β-catenin dependent-) Wnt pathway 
ligand. In this “canonical” pathway Wnt-3a binds to the receptor Frizzeld and to the co-
receptor LRP6 to inhibit the destruction complex and stabilizes β-catenin (Gordon and Nusse 
2006; Angers and Moon 2009). But Avila et al. (2010) detected that Wnt-3a can also activate 
the “non-canonical” Ca2+ dependent pathway in mature hippocampal rat neurons.  
Our working group was able to show, that Wnt-3a activates the β-catenin dependent Wnt 
pathway (Hübner et al., 2010, Mazemondet et al., 2011) as well as (the β-catenin 
independent) Ca
2+
 pathway (personal communication: V. Talabatulla) in ReNcell VM cells. In 
addition, Wnt-3a was able to increase the neuronal differentiation of ReNcell VM cells, 
shown in Wnt-3a overexpressing cells and cells treated with recombinant protein. In detail, 
Wnt-3a augmented HuC/D and Tuj1 positive cells, while stabilized β-catenin failed to mimic 
this effect (Hübner et al., 2010). This led to the suggestion of a β-catenin independent effect 
of Wnt-3a on ReNcell VM cells. In this work, the induction of the neuronal differentiation by 
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treatment with recombinant Wnt-3a was confirmed (Figure 16). In addition, a reduction of 
GFAP was detectable, while S100β was not affected (Figure 16). Similar results were 
detected via Wnt-3a transfection, where the transcript levels of the stem cell marker Nestin 
were reduced by Wnt-3a overexpression but not by overexpression of S33Y, the stabilized 
form of β-catenin (Hübner et al., 2010). This suggests that Wnt-3a increases the neuronal 
differentiation by reducing the stem-cell-ness of ReNcell VM cells and therefore pushing the 
cells to differentiation.  
Simultaneously, Wnt-3a modulated the Notch target genes HES1 and HES5. As outlined 
above, HES genes are known to regulate neurogenesis as well as gliogenesis in a plurality of 
different cell models (Ohtsuka et al., 2001; Wu et al., 2002; Kageyama et al., 2008). Precisely, 
HES5 was downregulated after 3 h up to 24 h with a short period without a significant 
downregulation at 8 h and 12 h of treatment (Figure 14). In contrast, HES1 was upregulated in 
early time points (2 h, 6 h and 8 h) and not significantly regulated in later time points (Figure 
14). Compared to Hirsch et al. (2007), where the HES5 mRNA levels were regulated in the 
same way, while HES1 levels were decreased after 24 h-treatment with Wnt-3a in neonatal 
mouse cortical neural progenitors. The differences may be occurring due to the source of the 
cell lines and the different cell contexts. Furthermore, HES1 is known to be modulated by 
different pathways such as the Wnt signaling pathway in a cell context dependent manner 
(Peignon et al., 2011), this interaction may cause the differential regulation. While Jörgi et al. 
(2002) described, that it is possible that differentiation is initiated by a short-lived 
upregulation of HES1 (in PC12 cells), DAPT treatment, which induced a fast and strong 
downregulation of HES1, clearly resulted in a marked increase in neuronal differentiation. 
This displays that the short induction of HES1 is not mandatory for the differentiation in 
ReNcell VM cells. But the strong, fast and consistent modulation of HES5 led to the 
suggestion, that it is directly regulated by Wnt-3a and is important for the neural 
differentiation. Furthermore, it seems to be sufficient to downregulate HES5 for 24 h to 
influence the differentiation as seen by Wnt-3a treatment.  
The mRNA level of GFAP was significantly downregulated by Wnt-3a after 6 h (Figure 14, 
C). This short time delay of 6 h may be due to an indirect regulation of GFAP. As outlined 
before, GFAP is in the majority of cases directly upregulated by HES5 and only in a second 
plain by Wnt-3a. But compared to the HES5 mRNA levels, GFAP levels did not get back to 
control levels after 24 h, instead, they kept downregulated. In sum, these data show that Wnt-
3a induces a temporary HES5 downregulation which in consequence potentially leads to a 
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reduction of GFAP. This effect may be caused by a disruption of the HES oscillation. It is 
known, that the oscillation of HES genes is important such as for a functional segmentation 
clock, but also occurs in the proliferation and differentiation of stem cells (Kageyama et al., 
2007, Kageyama et al., 2012). In addition, Nakaya et al. (2005) described Wnt-3a as a 
modulator of this segmentation clock, by regulating the Delta/Notch pathway. But in 
comparison, DAPT was not able to reduce GFAP in a stronger way than Wnt-3a, despite it 
had a stronger effect on HES5 mRNA levels at all-time points. This suggests that HES5 may 
be a mediator of the Wnt-3a effect but does not solely regulate GFAP, which is also 
observable by HES5 overexpression where GFAP mRNA levels were reduced (Figure 27). It 
is also possible, that the disruption of the putative HES5 oscillation led to a more prominent 
effect when it occurs at an early time point (up to 24 h) and when the oscillation is restored 
after 24 h. To further analyze the effect of the HES oscillation on differentiation it would be 
needed to do single cell analysis. Due to the fact, that ReNcell VM cells are not synchronized, 
an oscillation would likely not be detected by total mRNA or protein level analysis.  
Interestingly, MASH1 significantly increases after 24 h of Wnt-3a treatment, when HES1 is 
no longer upregulated but HES5 displayed its strongest downregulation (Figure 14). On the 
first glance this would suggests a HES5 dependent regulation of MASH1 and not a HES1 
dependent regulation, as it was described by Kageyama et al. (2008). But Fischer et al. (2007) 
reported a model in which HES1 is able to be an activator of MASH1 by binding to the 
transcriptional co-factor CBP or, in contrast, be a repressor by binding to the transcriptional 
co-factor TLE. The fact that MASH1, HES1 and HES5 were stronger affected by DAPT than 
by Wnt-3a, leads to the suggestion that MASH1 is a direct target of HES and, while HES is a 
target of Wnt-3a, only an indirect target of Wnt-3a. In this case, it is not possible to 
discriminate which HES regulates MASH1 or if both are necessary. Further analysis with a 
specific knockdown of HES1 and/or HES5 may reveal an answer to that question. 
Unfortunately, a knockout of one of the two HES genes in mice did not lead to a phenotype, 
only double knockout mice exhibit premature neurogenesis (Hatakeyama et al., 2004), which 
may be due to a potential compensatory effect.  
While Wnt-3a is able to modulate Notch target genes and DAPT is more potent to do that, it 
arises the question if it is able to act in addition to DAPT. A direct regulation of Notch by 
Wnt-3a is not probabilistic to be the solely modulator of the “Wnt-3a-effect” on neuronal 
differentiation, because Wnt-3a was able to modulate the Notch target genes in reverse 
directions and GFAP in a more secular way than DAPT. Therefore, the cells were treated in 
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combination with Wnt-3a and DAPT and were compared to DAPT single treatment. This 
method visualizes the additive effects of Wnt-3a on target genes compared to DAPT (Figure 
15). Strikingly, Wnt-3a was still able to upregulate HES1 mRNA level after 2 h of treatment 
despite the downregulation of HES1 using DAPT. In total, HES1 mRNA was 3-fold 
upregulated compared to DAPT single treatment, respectively, around 1.5-fold compared to 
HSA/DMSO. But after 6 h and 48 h, Wnt-3a reduced the HES1 mRNA level even further 
than DAPT alone. So there is an additive effect of Wnt-3a on HES1 mRNA detectable, but its 
effect seems to be time dependent. In contrast, the downregulation of HES5 mRNA was 
further decreased by Wnt-3a, compared to DAPT alone, in nearly all time points analyzed. 
This shows a more distinct impact of Wnt-3a on HES5 than on HES1 mRNA levels. Together 
with the observation that DAPT had also a more potent effect on HES5 than on HES1, HES5 
seems to be straighter regulated than HES1 in differentiating ReNcell VM cells. 
The GFAP mRNA level was already after 3 h of double treatment with DAPT+Wnt-3a 
significantly downregulated compared to DAPT alone (Figure 15). This implies a strong 
additive effect of Wnt-3a on the regulation of not only direct Notch target genes, but also on 
the proposed indirect target of Notch, namly GFAP. In addition, the effect on mRNA level 
was verified with FACS analysis, where the DAPT+Wnt-3a treated cells positive for GFAP 
were significantly decreased compared to DMSO as well as compared to DAPT (Figure 16). 
Simultaneously, Wnt-3a had no additive effect on the mRNA level of the proneural gene 
MASH1 (Figure 15) and nor on the amount of cells positive for the neuronal markers HuC/D 
and Tuj1 compared to DAPT single treatment (Figure 16). But in both cases was a 
tangentially increase detectable, which was significantly when compared to DMSO. The Wnt-
3a effect and the additive effect of Wnt-3a compared to DAPT treated neural progenitor cells 
is described for the first time in this work. This outstanding decrease of GFAP positive cells 
in combination with the highest increase of cells positive for the neuronal markers is a 
remarkably step forward to drive NPCs to neurons instead of glial cells. In conclusion, Wnt-
3a seemed to have a straight effect on HES5, which in turn had a straight effect on GFAP and 
MASH1, which finally regulated the fate of differentiating ReNcell VM cells to an increase in 
neuronal differentiation and a decrease of GFAP (Figure 16). In contrast, DAPT had a more 
potent effect on HES1 and HES5 and maybe, therefore, a stronger effect on MASH1 and on 
the differentiation to neurons but affected GFAP less potent than Wnt-3a. This lead to the 
suggestion that Wnt-3a upregulates the neuronal differentiation by reduction of the stemness, 
which can act in addition to the DAPT-induced increase of neurogenesis. 
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4.4 Time dependency in the differentiation of ReNcell VM cells 
The cells were treated once with Wnt-3a (100 ng/ml) at the beginning of differentiation (time 
point 0 h), this may be the reason why Wnt-3a lost its impact on HES genes after 24 h. 
Taelman et al. (2010) clearly showed a sequestration of the Wnt induced receptor signaling 
complex into multivesicular bodies but were not able to finally discover the fate of the Wnt 
ligand. They found a co-localization of the multivesicular bodies and Rab7, a lysosomal 
marker, which may led to the suggestion that the Wnt ligand can be degraded in the 
lysosomes and therefore depleted. Taken together, Wnt-3a may lose its impact on target genes 
because it was depleted during differentiation. 
It is widely known that the output of the Wnt signaling pathway and also of the Notch 
pathway is extremely cell context dependent. In addition, the time plays a major role, too. 
This led to the analysis of the time dependency of the “DAPT/Wnt-3a effect” on 
differentiating ReNcell VM cells, which was not described before in the literature and, 
therefore, is a complete new experimental design. Cells were treated once with substances, 
these were washed out after an indicated time period and after a total of three days of 
differentiation cells were analyzed. All cells were differentiated for three days but with a 
changing time frame of differentiation, in combination with substances. In all analyzed 
markers the first significant effects were detectable after 24 h of treatment, while the strongest 
effects were reached after 48 h of treatment (Figure 18). This reveals a time frame were the 
substances are able to effect the differentiation of ReNcell VM cells. In sum, the cells have to 
be treated for at least 24 h to direct them into a neuronal fate. A longer treatment of 48 h, 
results in a stronger effect, but a treatment for 72 h did not resulte in a further augment. This 
suggests that the effect is saturated after 48 h and a further increase is unlikely.  
The differences between the two neuronal markers HuC/D and Tuj1 are of interest. While the 
first Tuj1 positive cells were detectable after treatment for 24 h, the first HuC/D positive cells 
were observable after treatment for 3 h, where all cells were differentiated for 3 days (Figure 
18). This indicates HuC/D as a very fast and sensitive neuronal marker. Hu proteins are RNA-
binding proteins to stabilize specific target mRNAs, HuC and HuD are, therefore, the earliest 
markers of the neuronal cell lineage (Perrone-Bizzozero and Bird 2013). In contrast Tuj1 is a 
β-tubulin which is able to heterodimerize with α-tubulins to form microtubules, which are 
essential components of the cytoskeleton. And it is a marker for terminally differentiated 
neurons of the central and peripheral nervous system (Perrone-Bizzozero and Bird, 2013). 
Therefore, the time-dependent differences of the neuronal markers are due to the different 
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source of the protein-marker. This means, a RNA-binding protein is usually faster affected by 
a cellular signal than a cytoskeleton protein and therefore a faster and more sensitive marker 
for changes in cell fate. This was, in addition, visible by cells differentiated for only 24 h. 
There was the significant effect of treatment detectable, precisely DAPT and DAPT+Wnt-3a 
were able to increase the amount of HuC/D positive cells compared to control (Figure 19). 
Interestingly, the only significant reduction of S100β was detectable after 48 h of treatment 
with DAPT+Wnt-3a compared to DMSO (Figure 18). The effect was lost after 72 h of 
treatment due to the high standard deviation. But it shows that double treatment can have an 
effect on astrocytes and led not only to an increase of cells positive for neuronal markers.  
To increase the neuronal differentiation, the cells needed to be treated right after the start of 
differentiation with the substances. After 18 h of differentiation the cells were able to change 
the differentiation program to neuronal differentiation, demonstrated by the increase of 
HuC/D positive cells, but were not able to finally differentiate into more mature -Tuj1 
positive cells (Figure 20). As described above, HuC/D is an early marker for neuronal 
differentiation and therefore can be seen as a marker which is able to detect the beginning 
changes in neuronal differentiation. Tuj1, on the other hand, is a marker for more mature 
neuronal differentiation and therefore detects the final amount of mature neurons, 
respectively, the final outcome of the differentiation. The treatment did not have any effect on 
the amount of mature neurons, if treated after 24 h or 66 h (Figure 20). Simultaneously, the 
amount of cells positive for S100β and GFAP were not affected when treated after the start of 
differentiation. In summary, the cells have to be treated at the beginning of differentiation to 
significantly increase the amount of mature neurons and decrease the amount of GFAP 
positive cells. This shows that the cells need time to react on the treatment and also to run the 
whole differentiation program to finally differentiate into mature neurons.  
 
4.5 The mechanism behind the Wnt-3a effect 
The two major pathways controlling neuronal and glial differentiation are the Wnt and Notch 
Signaling pathways (Kunke et al., 2009; Kageyama et al., 2005). Over the past years, it 
became obvious that crosstalk of these pathways is fundamental in controlling events during 
vertebrate and non-vertebrate development. This work assessed the role of Notch signaling 
and its crosstalk with the Wnt/β-catenin pathway in the human neural progenitor cell line 
ReNcell VM.  
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4.5.1 Wnt pathway dependency 
Our group previously showed that Wnt-3a as well as stabilized β-catenin and inhibition of 
GSK3 activate target genes of the Wnt/β-catenin pathway in ReNcell VM cells (Hübner et al., 
2010; Mazemondet et al., 2011; Schmöle et al., 2010). Hübner et al. (2010) revealed 
moreover that Wnt-3a, but not stabilized β-catenin, is able to increase neurogenesis. In 
addition, stabilized β-catenin was not able to modulate Notch target genes HES1/HES5 or 
GFAP (Rayk Hübner, personal communication). This leads to the suggestion, that Wnt-3a 
may modulate the Notch pathway in ReNcell VM cells over Wnt-pathway-proteins upstream 
of β-catenin. 
The main Wnt-pathway-protein upstream of β-catenin, which is known to be able to modulate 
a variety of different proteins such as SMAD1 and Notch, is GSK3β (Ribeiro et al., 2009). 
Taelman et al. (2010) detected that over 20 % of the proteome containing three or more 
consecutive potential GSK3 sites. Furthermore, Espinosa et al. (2003) suggested that Notch 
phosphorylation by GSK3β regulates crosstalk between the Notch and Wnt pathways. While 
Wnt-3a inhibits the GSK3β, its inhibition with small molecules should mimic the effects of 
Wnt-3a. But in ReNcell VM cells the inhibition of GSK3β by SB216763 and IM12 was not 
able to mimic the effect. While SB216763 was able to increase the mRNA level of AXIN2, it 
did not augment the mRNA levels of HES1, did not reduce HES5 or GFAP levels (Figure 21) 
in the same way like Wnt-3a and did not increase the amount of cells positive for HuC/D and 
Tuj1 or reduced the amount of GFAP positive cells (Figure 22). Interestingly, SB216763 
reduced HES1 as well as HES5 mRNA levels in later time points and reduced the amount of 
cells positive for the mature astrocyte marker S100β. In summary, SB216763 did not mimic 
the effect of Wnt-3a and therefore seemed not to be the link between the Wnt and Notch 
pathway in ReNcell VM cells. While Taelman et al. (2010) described stabilized β-catenin as 
an inducer of the sequestration of the signaling complex (containing Wnt-3a, LRP6 as well as 
GSK3β) and while this sequestration inhibits GSK3β, confirms the inhibition of GSK3 that 
the Wnt-3a effect is independent of β-catenin.  
There are plenty of different Wnt pathways known in the literature. Beside the best described 
pathway the β-catenin dependent pathway there are, in addition, a rising number of β-catenin 
independent pathways described. The main β-catenin independent pathways are the PCP- and 
Ca
2+
-pathway but there are additional downstream events triggered by Wnts in combination 
with Frizzled or specific co-receptors like ROR and RYK (Niehrs 2012). In all described β-
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catenin dependent pathways the co-receptor LRP5/6 is involved. The binding of Wnt to the 
co-receptor LRP5/6 can be inhibited in NPCs by Dkk-1 (Munji et al., 2011).  
In ReNcell VM cells the effect of Wnt-3a on the mRNA level of Notch target genes is not 
inhibited by Dkk-1 while AXIN2 is significantly decreased (Figure 23). In addition, the 
induction of HuC/D and Tuj1 positive cells by Wnt-3a is as well not inhibited by Dkk-1 (see 
appendix 7.5). Furthermore, Dkk-1 treatment led to an additional decrease of HES5 mRNA 
level. This additional effect suggests a competitive mechanism of Wnt-3a in which Wnt-3a, 
can activate the β-catenin dependent pathway by binding to LRP and simultaneously activates 
the unknown “β-catenin, GSK3 and LRP independent” pathway. These two pathways are in 
competition with each other for the Wnt-3a ligand. One can speculate that Dkk-1 inhibits the 
“β-catenin, GSK3 and LRP dependent” pathway, thus raising the level of Wnt-3a available to 
activate the “β-catenin, GSK3 and LRP independent” pathway which further decreases HES5. 
A similar effect was described by Nalesso et al. (2011). They found that Wnt-3a can 
simultaneously activate the β-catenin dependent pathway and the Ca2+ pathway with distinct 
and independent outcomes in human articular chondrocytes.  
In contrast, the inhibition of the Wnt-3a and Frizzled receptor interaction by sFRP1 did not 
significantly modulate HES5 mRNA level compared to control, but increased it by tendency 
(Figure 24). To more clearly verify the impact of Frizzled in this pathway a better AXIN2 
inhibition is needed to get a better view of the dependencies. Nevertheless, these data suggest 
a Wnt-3a effect which is not trigged by LRP or GSK3 neither by β-catenin. But it leads to the 
suggestion of an activation of a β-catenin independent pathway by Wnt-3a which was already 
demonstrated by V. Talabattula (personal communication) who was able to induce Calcium 
signaling by Wnt-3a treatment in ReNcell VM cells. In addition, the increase of components 
of the PCP pathway in differentiating cells suggested a possibly active or activatable pathway 
(Mazemondet et al., 2010). In addition, it is highly improbable RYK dependent due to the fact 
that it is activated by the cleavage of a γ-secreatase which releases its intracellular domain and 
starts transcription after translocation into the nucleus (Lyu et al., 2008). If the Wnt-3a effect 
depends on this pathway DAPT would inhibit this cleavage and, therefore, no additive effect 
of Wnt-3a and DAPT compared to DAPT would be detectable. In contrast, DAPT would 
inhibit the effect of Wnt-3a on the RYK dependent pathway. 
In sum, the effect of Wnt-3a is independent of β-catenin, of the upstream protein GSK3β, of 
the co-receptor LRP5/6 and seems to be independent of the receptor Frizzled. Up to now there 
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is no pathway known in which Wnt is able to activate a pathway independent of Frizzled, 
therefore, independency of Frizzled should be verified.  
4.5.2 Notch pathway dependency 
As described before, the effect of DAPT on ReNcell VM cells depends on the Notch 
intracellular domain 1 (NICD1). In addition, the effect of Wnt-3a depends as well as DAPT 
effects on NICD1. As long as NICD1 was overexpressed, neither DAPT nor Wnt-3a was able 
to increase neurogenesis (Figure 25). This led to the suggestion that the DAPT as well as the 
Wnt-3a effect on neuronal differentiation depends on the Notch intracellular domain 1, which 
was able to augment HES5 while HES1 was decreased and without HES1 and HES5, NICD 
was unable to inhibit neurogenesis (Kageyama et al., 2008). To verify this effect of the 
NICD1, HES1 and HES5 were overexpressed. The overexpression of HES5 led to an 
inhibition of the neuronal differentiation of ReNcell VM cells (Figure 27). The inhibitory 
effect of HES5 on differentiation was described before in NSCs by Kageyama et al. (2008) 
and in rat embryonic neural stem cells by Liu et al. (2010). In contrast, DAPT, which inhibits 
HES5, was described to reduce proliferation and increase differentiation (Nelsen et al., 2007, 
Borghese et al., 2010). This was shown in the reduction of the stem cell marker GFAP in 
ReNcell VM cells. Unfortunately, the reduction of Wnt-3a+DAPT treated GFP-transfected 
cells positive for GFAP compared to HES5 overexpressing cells under control-treatment was 
not significant (Figure 27). This may be due to the experimental procedure since cells were 
transfected and transfected cells generally showed a higher amount of cells positive for 
GFAP.  
Interestingly, the overexpression of HES1 inhibited the differentiation of the progenitor cells 
(Figure 30) but not to the same extent like HES5, while the amounts of HES transcripts in the 
overexpressing cells were similar. This led to the suggestion that HES5 had a stronger effect 
on differentiation than HES1. Furthermore, overexpression of HES5 (Figure 27) resulted in a 
stronger decrease of HuC/D and Tuj1 positive cells compared to HES1 overexpressing cells 
(Figure 30). In addition, the substances DAPT and Wnt-3a were still able to increase the 
amount of HuC/D positive cells when HES1 is overexpressed (Figure 30). In contrast, HES5 
overexpressing cells were not affected by the substances (Figure 27). These data strongly 
suggest that HES5 is a modulator of the effect of Wnt-3a as well as DAPT. Simultaneously, 
the mRNA levels of HES5 and HES1 correlate with each other. Precisely, HES1 
overexpression leads to a reduction of HES5 (Figure 31) and vice versa (Figure 28). The 
bilateral interaction of HES proteins was described before in mouse C3H10T1/2 cells by 
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Takebayashi et al. (1994) and in mouse spinal cord by Wu et al. (2002). But Hatakeyama et 
al. (2004), in addition, described that the HES proteins were able to compensate each other. 
But, it is the first time that this effect is verified in human neuronal progenitor cells. This may 
explain that the HES1 overexpressing cells did have a decreased amount of Tuj1 and HuC/D 
positive cells, despite HES5 was downregulated. Moreover, HES5 (Figure 28) as well as 
HES1 (Figure 31) overexpressing cells showed the expected downregulation of MASH1 
mRNA levels. This fits to the upregulation of MASH1 under DAPT treatment (Figure 11), 
where in contrast the HES1 and HES5 mRNA levels were downregulated. Unfortunately, due 
to the potential compensatory effect and the bilateral interaction it was not possible to finally 
clarify which HES regulates MASH1. The MASH1 regulation is controversially discussed in 
literature. Cao et al. (2010) revealed a HES5 dependent regulation of MASH1 in striatal 
tissues from E14-E15 mouse embryos, while Zhang et al. (2009) described that HES1 
repressed the transcription of MASH1 in mouse NPCs from the anterior subventricular zone. 
In contrast, Fischer et al. (2007) suspected that HES1 can function as an activator as well as 
an inhibitor of MASH1 depending on the present co-transcription factors. Precisely, they 
suppose that HES1 in combination with TLE (transducing-like enhancer of split) repress 
MASH1 and HES1 in combination with CBP (CREB binding protein) activates MASH1. In 
sum, without a deletion of HES1 or HES5 it will not be possibly to clarify wich HES is 
responsible for MASH1 regulation and even than it is difficulte to answer that question due to 
their compensatory effect. Therefore the MASH1 poromotor has to be analyzed to verify 
which HES binds to it. 
Strikingly, the GFAP mRNA levels were clearly decreased by HES1 (Figure 31) and HES5 
(Figure 28) overexpressing cells. However, the amount of GFAP positive cells was not 
affected (Figure 27 and Figure 30). It was suggested that decreased HES5 levels would lead to 
a decrease of GFAP as shown by Kabos et al. (2002) and Wu et al. (2002). In addition, Ijuin 
et al. (2008) reported that HES1 and HES5 overexpression induces GFAP expression in 
mouse mesencephalic neural crest cells, which were also GFAP positive in proliferation as 
ReNcell VM cells. This contradicts the results in ReNcell VM cells. The decrease of GFAP 
mRNA level was detectable at all time points between 0 h and 72 h and is not in line with the 
not changed amount of cells positive for GFAP. The differences may be due to the distinct 
methods used, the flow cytomeric analysis counts only positive cells but does not show a 
downregulation of the amount of GFAP protein in GFAP positive cells (data not shown). A 
feedback regulation is partially possible, due to the fact that GFAP mRNA level was 
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downregulated in all time points but the amount of positive cells was not changed after 3 days 
of differentiation. If a feedback regulation of GFAP would be true in ReNcell VM cells, this 
would lead to the suggestion that GFAP proteins have a very long half-life. Interestingly, 
Rolland et al. (1990) analyzed the expression and turnover of GFAP in astroglial primary 
cultures. They found via radioactive labeling two pools of GFAP, the first one was a fast 
decaying pool with a half-life of 16-18 h and the second was a stable one with a half-life of 5-
6 days. It is possible that the overexpression of HES1 and HES5 led to a decrease of the 
mRNA level of GFAP, but the amount of cells positive for GFAP was not affected due to the 
protein half-life of 5-6 days. To check this hypothesis the amount of cells positive for GFAP 
should be analyzed after 6-7 days. It is not much known about the different GFAP pools, but 
they may occur due to distinct splice variations of GFAP. Thomsen et al. (2013) revealed that 
at least two of the 8 known splice variants have distinct subcellular localization patterns. In 
this work a qRT-PCR primer was used which is able to detect all splice variations without the 
variation GFAPγ. Therefore it can be speculated that GFAPγ may be the upregulated protein 
which is measured by flow cytometry while its mRNA level was not able to be detected.  
 
4.5.3 BMP pathway dependency 
The target genes ID1 and ID3 are the best described target genes of the BMP pathway 
(Obayashi et al., 2009). They were described to be regulated not only by BMP but 
additionally by Wnt-3a in C2C12 cells (Nakashima et al, 2005). Precisely, Fuentealba et al. 
(2007) revealed that GSK marked SMAD1 for degradation by phosphorylation. In contrast, 
Guo et al. (2009) described that Wnt-3a activates, over AXIN2 induction, the BMP inhibitor 
SMAD7. In ReNcell VM cells, Wnt-3a was not only able to decrease ID1 but, in addition, 
ID3 (Figure 32). However, inhibition of the BMP pathway was not able to mimic the effect of 
Wnt-3a. There are three well described substances to inhibit the BMP pathway. Noggin binds 
the ligand BMP2, 4 and 7 and therefore inhibits the SMAD1, 5, 8 and MAPK p38 (Yu et al., 
2008). Dorsomorphin inhibits BMP4 induced signaling and does not affect MAPK p38 (Yu et 
al., 2008). SB431542 inhibits the TGF-β signaling pathway and therefore SMAD2 and 3 
(Inman and Hill, 2002). Noggin led to an increase of HES5 mRNA level and simultaneously 
decreased the amount of HuC/D positive cells (Figure 33). Dorsomorphin did not affect HES5 
or GFAP mRNA levels but reduced the amount of cells positive for HuC/D and Tuj1 (Figure 
34). SB431542 treatment, in addition, was not able to affect the differentiation of ReNcell 
VM cells (Figure 35). This clearly showed that HES5 is not solely mandatory for the decision 
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if cells differentiate into neurons or not, otherwise the HES5 mRNA level would be 
augmented by Dorsomorphin alike by Noggin treatment. In sum, the reduction of ID1 and/or 
ID3 did not led to the increase of cells positive for neuronal marker by Wnt-3a treatment, due 
to the fact that ID reduction by BMP inhibitor led to a decrease of neurons. The differences 
between the inhibitors Noggin and Dorsomorphin may be due to the different inhibitory 
mechanisms. While Noggin binds the ligand BMP2, 4 and 7 and therefore inhibits the 
SMAD1, 5, 8 and MAPK p38, Dorsomorphin inhibits BMP4 induced signaling and does not 
affect MAPK p38 (Yu et al., 2008). But when the inhibition of ID led to a decrease of neurons 
it arises the question whether the Wnt-3a induced ID reduction counteracts the induction of 
neuronal differentiation. Thus ID1 and ID3 may have a compensatory role in regulating 
neuronal differentiation.  
 
4.5.4 JAK/STAT3 pathway dependency 
The signal transducer and activator of transcription 3 (STAT3) was described to negatively 
regulate the neuronal differentiation by regulating, in combination with other transcription 
factors, proneural genes and to stimulate astrogliogenesis by activating GFAP (Rajan et al., 
1998 Nakashima et al., 1999). STAT3 is a transcription factor which, upon phosphorylation at  
Tyr 705 forms dimers and translocates to the nucleus (Darnell et al., 1994). Therefore an 
analysis via qRT-PCR would not be useful compared to other transcription factors which are 
not known to be regulated by posttranslational modifications like the bHLH genes HES1, 
HES5 and MASH1. In addition, no post-translational modifications are known for GFAP. The 
activation and translocation can be triggerd with the small molecule AICAR (Zang et al., 
2008) and inhibited by Jak-Inhibitor-1 (Pedranzini et al., 2006).  
At first, the detection of phosphorylated STAT3 in ReNcell VM cells demonstrated an active 
JAK/STAT3 pathway (Figure 36). In addition, AICAR was able to activate STAT3 and led to 
an augment of pSTAT3 in the nucleus, while Jak-Inhibitor-1 was only able to decrease the 
amount of pSTAT3 by tendency (Figure 36). Interestingly, cells treated with Jak-Inhibitor-1 
showed a less differentiated phenotype than control cells (Figure 37). Constitutively active 
STAT3 was observed in a large number of human tumors stimulating cell proliferation and 
preventing apoptosis. The inhibition with Inhibitor 2 ((E)-2-cyano-N-[(S)-1-phenylethyl]-3-
(pyridin-2-yl) acrylamide), in contrast, led to an induction of apoptosis in glioma cells 
(Swiatek-Machado et al., 2012). In ReNcell VM cells an obvious increase of apoptosis was 
not detectable via microscopy analysis, but an apoptosis assay would maybe reveal clearer 
Discussion  97 
 
 
results. In addition, AICAR was able to strongly reduce the amount of cells posit ive for the 
neuronal marker HuC/D and Tuj1 while Jak-Inhibitor-1 only reduced them by tendency 
(Figure 38). In contrast, the amount of GFAP positive cells were increased by AICAR but not 
affected by Jak-Inhibitor-1 treatment (Figure 38).  
In sum, pSTAT3 was found in ReNcell VM cells and AICAR was able to induce the 
phosphorylation of STAT3 at Tyr 705 and the subsequent dimerization and translocation to 
the nucleus. The activation of the STAT pathway led to a decrease of neuronal differentiation 
and an increase of GFAP positive cells. This shows that the JAK/STAT3 pathway is active, is 
able to be modulated in ReNcell VM cells and its activation inhibits differentiation.  
The γ-secretase inhibitor DAPT inhibits the Notch pathway and, therefore, reduces the 
amount of HES1 and HES5 in ReNcell VM cells (Figure 11). Kamakura et al. (2004) revealed 
that STAT3 is an effector of HES1 and HES5 mediated astrocytic differentiation in mice. 
They described HES as scaffolding proteins that induces STAT3 phosphorylation by JAK2 
and, therefore, induces GFAP expression. This work revealed that the treatment with DAPT 
leads to a reduction of pSTAT3 (Figure 39) which maybe caused by the inhibition of HES1 
and HES5. In contrast, the inhibition of PKC using the inhibitor GF109203X in ReNcell VM 
cells (Hübner, 2010), which subsequently activates the phosphorylation of pSTAT3 
(Mattagajasingh et al., 2012), leads to an increase of Tuj1 and HuC/D positive cells. This 
underlines the impact of pSTAT3 on the differentiation of human neural progenitor cells. 
Furthermore, AICAR was able to inhibit the effect of DAPT on differentiating ReNcell VM 
cells (Figure 40). A small augment of pSTAT3 caused by AICAR seems therefore, to be able 
to inhibit the strong effect of DAPT. In sum data suggest, that the inhibitory effect of DAPT 
on the notch pathway is able to increase the neurogenesis by reduction of the active, while 
post-translational phosphorylated, STAT3. In contrast, the regulation of Wnt-3a seems to be 
independent of the post-translational phosphorylation of STAT3 because it did not 
significantly affect pSTAT3 (Figure 39). 
Doubtful is the fact that GFAP is mainly regulated by STAT3, due to the fact that in ReNcell 
VM cells Wnt-3a (Figure 13) downregulates GFAP mRNA level stronger than DAPT (Figure 
11). If STAT3 would primarily regulate the transcription of GFAP a decrease of pSTAT3 
would lead to a decrease of GFAP mRNA. But the decrease of pSTAT3 was only detected by 
DAPT treated cells (Figure 39) and the decrease of GFAP mRNA was stronger and faster by 
Wnt-3a treated cells compared to DAPT treated cells. This contradicts the mechanism of a 
mainly by STAT3 regulated GFAP. It can be speculated that this contradicting regulation may 
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be due to the two different GFAP pools with different half-lifes. Hypothetically, DAPT may 
downregulate the stable GFAP pool over pSTAT3, which is detectable by FACS but not by 
qRT-PCR due to the splice variant GFAPγ. Wnt-3a, in contrast, maybe downregulates only 
the instable GFAP pool, GFAP mRNA levels without the GFAPγ, over a yet unknown 
mechanism.  
 
4.6 Induced pluripotent stem cell derived neural progenitor cells (iPS-
NPCs) 
To verify that the described effects in ReNcell VM cells are not a cell-type specific 
phenomenon a second cell line was used. This cell line consists of neural progenitor cells 
which were derived from induced pluripotent stem cells. These cells express the same neural 
markers like ReNcell VM cells, Nestin and SOX2, and are able to differentiate into neuronal 
cells. 
This work revealed that iPS-NPCs exhibit an active Notch pathway, detectable by HES1 and 
HES5 expression, which is able to be inhibited by DAPT (Figure 41). Interestingly, DAPT 
reduced the mRNA level of HES5 stronger than the HES1 mRNA level. These results are in 
common with the ReNcell VM cell results (Figure 11). But in contrast to ReNcell VM cells, 
the inhibition of HES1 and HES5 by DAPT did not change the amount of HuC/D positive 
cells and therefore had no detectable effect on neurogenesis in iPS-NPCs (Figure 43). This 
may be due to the high standard deviations or because of the already high (37 %) number of 
HuC/D positive cells compared to that 8 % of the ReNcell VM cells and suggest a saturating 
effect. The inhibition of the Notch pathway, furthermore, decreased the amount of cells 
positive for the glial marker S100β and GFAP (Figure 43). The amount of cells positive for 
the glial marker GFAP is, compared to ReNcell VM cells, strongly reduced, where 80 % of 
ReNcell VM cells and 14 % of iPS-NPCs are positive. This reduction may occur due to the 
fact that GFAP is a stemness marker in ReNcell VM cells and is already detectable in 
proliferating cells. In iPS-NPCs GFAP is solely a glial marker and may increase during 
differentiation length (Qian et al., 2000). The regulation of S100β by DAPT and DAPT+Wnt-
3a in iPS-NPCs (Figure 43) is a clear difference compared to ReNcell VM cells (Figure 11 
and Figure 15) and may be cell type specific. Another difference between ReNcell VM cells 
and iPS-NPCs is the speed of differentiation. While ReNcell VM cells need three days to 
differentiate into cells with neuronal morphology expressing neuronal markers, iPS-NPCs 
need at least 17 days. Since iPS-NPCs differentiated only for 48 hours in the presence of Wnt-
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3a –afterwards the medium was changed-, this treatment duration may not be sufficient to 
promote the effect on neuronal differentiation. Thus iPS-NPCs have to be treated in the whole 
time of differentiation which means to treat them after every change of medium again.  
Moreover, iPS-NPCs were able to respond to Wnt-3a. Precisely, Wnt-3a treatment led to an 
increase of active non-phosphorylated β-catenin protein, an augment of AXIN2 mRNA and to 
an induction of HES1 mRNA and a reduction of HES5 mRNA (Figure 42). These data 
demonstrate that Wnt-3a was able to activate Wnt/beta-catenin signaling accompanied by 
modulation of Notch pathway which was similar to ReNcellVM cells. In contrast, Wnt-3a was 
not able to affect the amount of cells positive for glial and/or neuronal markers (Figure 43). 
This may be due to high standard deviations, especially the cells positive for the glial markers 
were at least decreased by tendency. Furthermore, the additive effect of DAPT+Wnt-3a was 
similarly observable in iPS-NPCs (Figure 43) as well as in ReNcell VM cells (Figure 15). In 
both cell lines, Wnt-3a intensified the effects on HES1 and HES5 mRNA levels compared to 
DAPT treatment alone. This shows that even if Wnt-3a alone is not able to modulate HES 
genes and markers as effective as in ReNcell VM cells, the combinatory treatment is, like in 
ReNcell VM cells, able to strongly increase the effect of DAPT. The combination of DAPT 
and Wnt-3a, therefore, seems to activate an important mechanism of the neuronal 
differentiation in neural progenitor cells.  
In sum, the modulation of HES1 and HES5 by Wnt-3a and DAPT+Wnt-3a in ReNcell VM 
cells were verified in iPS-NPCs but the effect on neuronal markers was not confirmed. Tomita 
et al. (2001) revealed that in the absence of proneural genes such as MASH1 the neuronal 
differentiation is inhibited and neural stem cells remain in earlier stages. Thus, the absence of 
MASH1 may be the reason that the amount of cells positive for the neuronal marker HuC/D 
was not changed.  
 
4.7 ReNcell VM cells  
ReNcell VM cells are a v-myc retrovirally immortalized human cell line and were derived 
from the ventral midbrain of a 10-week old male fetus. V-myc is the viral homologe of c-myc 
and is the most potent transforming gene known. The potency of neural progenitors to 
differentiate is not influenced by v-myc. But a v-myc transformation inhibits the potential to 
diffentiate under treatment with substances like retinoic acid (Lee et al 1999). There is no Wnt 
or Notch mediated regulation of v-myc known. However, Liu et al., 2011 showed that c-myc 
is stimulated by Wnt-3a in intestinal epithelial cells (IEC-6) through LRP6 and β-catenin. 
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This result does not influence the veracity of this work due to the fact that the Wnt-3a effect 
shown in this work is not mediated through LRP6 and β-catenin. It is not known if the 
overexpression of v-myc is able to modulate the Wnt pathway. Recently Zinin et al., 2014 
discovered a negative regulation of Notch1, HES1 and HES5 by c-myc in radial glial 
precursors. In this work Notch1 is detactable in v-myc retrovirally transfected cell line 
(ReNcell VM cells) and seems not be strongly downregulated by v-myc. This maybe indicates 
a celltype specific regulation. In addition, HES1 and HES5 were detectable in ReNcell VM 
cells on RNA levels and protein levels.  
In sum, ReNcell VM cells are a fast differentiating cell line of neural progenitor cells. The 
speed of proliferation and differentiation is maybe due to the v-myc transfection, but it is 
unclear if v-myc is able to modulte the Wnt and Notch pathway. Therefore in this study was 
also a second cell line used, the induced pluripotent stem cell derived neural progenitor cells 
which showed similar results like the ReNcell VM cells. This shows that the v-myc 
overexpression is not essential for the descriped Wnt-3a effect. 
 
4.8 Outlook 
The ReNcell VM cells are fast differentiating cells which are able to express neuronal 
markers and show the typical neuronal morphology after three days of differentiation. In 
contrast, iPS-NPCs need at least 17 days to differentiate. Due to the short treatment periode of 
48 hours – afterwards the medium was changed - iPS-NPCs neuronal differentiation was not 
affected by treatment with Wnt-3a and DAPT. Thus iPS-NPCs have to be treated in the whole 
time of differentiation which means to treat them after every change of medium again. This 
could be done with conditioned medium from Wnt-3a overexpressing cells to reduce costs. 
To confirm HES5 as the main mediator of the Wnt-3a and DAPT effect on neuronal 
differentiation, a specific knockdown of HES1 and/or HES5 is needed. Even if a knockout of 
one of the two HES genes in mice did not lead to a phenotype (Hatakeyama et al., 2004) may 
lead a knockout in neuronal precursor cells to a significant difference in neuronal 
differentiation and/or in MASH1 mRNA levels. 
The inhibition of the Wnt-3a and Frizzled receptor interaction by sFRP1 did not significantly 
modulate HES5 mRNA level compared to control, but increased it by tendency (Figure 24). 
To more clearly verify the impact of Frizzled in this pathway a better AXIN2 inhibition is 
needed to get a better view of the dependencies. In addition an independency of Frizzled 
should be verified by a Frizzled knock out, because up to now there is no pathway known in 
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which Wnt is able to activate a pathway independent of Frizzled. This would be a completely 
new pathway induced by Wnt-3a. 
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5 Summary 
The aim of this study was to shed light on the poorly understood network of signaling 
pathways which are responsible for the cell fate determination and differentiation of human 
neural progenitor cells initiated by Wnt-3a treatment and Notch pathway inhibition.  
Wnt-3a was not only able to induce the β-catenin dependent Wnt pathway, but also regulated 
the Notch target genes HES1 and HES5 in a β-catenin independent manner, while stabilized 
β-catenin was not able to modulate them. Furthermore, Wnt-3a differentially regulated HES1 
and HES5 independent of the Notch pathway while additive to the inhibition of Notch by 
DAPT. This regulation was independent of the β-catenin dependent pathway, because it was 
independent of GSK3β inhibition, independent of the formation of a Wnt-3a-LRP6-Frizzled 
receptor complex and independent of the inhibition of the BMP signaling pathway which is 
known to be initiated by Wnt ligands through β-catenin. This all suggested a β-catenin 
independent mechanism and therefore an activation of the β-catenin independent pathway by 
Wnt-3a. In sum, Wnt-3a activated a signaling cascade which activated HES1 transcription and 
inhibited HES5 and subsequently inhibited GFAP and increased MASH1 transcription while 
the phosphorylation level of STAT3 was not affected by Wnt-3a. The involved receptor 
combination is still unknown but was independent of LRP6 and possibly of Frizzeld. 
Simultaneously, using iPS-NPCs in this study revealed for the first time that the modulation 
of the Notch target genes by Wnt-3a is a common mechanism in human neural progenitor 
cells. 
Wnt-3a was able to downregulate GFAP and upregulate MASH1 mRNA level which were not 
solely dependent on the modulation of HES5. Moreover, GFAP seemed to be stronger 
regulated by Notch inhibition through DAPT which in turn was strongly dependent on 
phosphorylated STAT3. AICAR, the inducer of pSTAT3, in contrast, could rescue the effect 
of DAPT on the amount of cells positive for GFAP. HES5, in the meantime, seemed to be 
involved in the glial differentiation but did not solely regulate the neuronal differentiation. 
Furthermore, HES5 seems to be regulated mainly by Notch and in ReNcell VM cells at least 
by NICD1, while HES1 was not solely modulated by Notch. 
In the differentiation of ReNcell VM cells Wnt-3a was able to repress BMP pathway target 
genes, but this reduction was not responsible for the increase in neuronal differentiation since 
the inhibition of BMP signaling led to a decrease of cells positive for neuronal markers. This 
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suggests that Wnt-3a simultaneously initiated pro- and antineurogenic signal cascades which 
underlines that the final outcome of differentiation strongly depends on the cell context. 
The differentiation of ReNcell VM cells needs 3 days to establish the maximal numbers of 
cells positive for the neuronal markers HuC/D and Tuj1. To modulate this process the first 
hours are crucial, 24 h after induction of differentiation the treatment is not anymore sufficient 
to increase neurogenesis. This demonstrates a defined time window for the modulation of the 
differentiation of ReNcell VM cells. 
In sum, the combined treatment with Wnt-3a and DAPT and the thereout resulting increase of 
cells positive for neuronal markers and decrease of stemness marker is an outstanding step 
forward to drive NPCs from an undifferentiated state to neurons instead of glial cells which is 
a prerequisite for cell based therapies utilizing neuronal cells. 
 
Figure 44: Simplified scheme of the crosstalk between Wnt-3a and the Wnt, BMP and 
Notch pathway in hNPCs. Blue: Wnt pathway components: when Wnt-3a binds to Frizzled 
and LRP5/6, GSK3β is phosphorylated and inactivated. This allows β‑catenin to accumulate 
and translocate to the nucleus, where it activates the transcription of target genes like AXIN2. 
SB216763 can be used to inhibit GSK3β like Wnt-3a and S33Y is a stabilized form of β‑
catenin which is able to activate target genes upon overexpression. Red: BMP pathway 
components: Wnt-3a is able to inhibit the BMP pathway which does not lead to increased 
neuronal differentiation in hNPCs. BMP can also be inhibited by Dorsomorphin, SB431542 
and Noggin. Green: Notch pathway components: The notch receptor is cleaved by γ-secretase 
to release NICD which translocates to the nucleus and starts transcription of the target genes 
HES. 
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7 Appendix 
7.1 ReNcell VM cells 
 
Figure 45: Phasecontrast picture of ReNcell VM cells in proliferation and differentiation. A: Phasecontrast 
of proliferating ReNcell VM cells. B: Phasecontrast of 3 days differentiated ReNcell VM cells. 
 
7.2 iPS-NPCs 
 
Figure 46: Phasecontrast picture of iPS-NPCs in proliferation and differentiation. A: Phasecontrast of 
proliferating iPS-NPCs. B: Phasecontrast of 18 days differentiated iPS-NPCs. 
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7.3 Efficiency of transfection and lipofection of ReNcell VM cells 
  
Figure 47: Efficency of transfection and lipofection. A: Transfection of 1 Mio ReNcell VM cells with 
pCAGGS-GFP, 24 h after transfection of 4 µg plasmid DNA. B: Lipofection of 0,2 Mio HEK293H with 
pCAGGS-GFP, 24 h after lipofection of 4 µg plasmid DNA. 
 
7.4 Generation of pCAGGS-HA-HES vectors 
7.4.1 Generation of pCAGGS-HA-hHES1 
To amplify hHES1 the plasmid pCMV6-XL4-HES1 (origene) was used as a template, 
together with the forward primer which includes the XhoI restriction site in combination with 
a HA-Tag and the reverse primer which includes a BstXI restriction site. After amplification 
of HA-hHES1 (Figure 48, A) the insert was purified and ligated into pGEM-T easy (Promega) 
for subsequent blue/white screening and selection. Positive clones were analyzed by digestion 
with BstXI and XhoI, expected fragments were ca. 3000 bp and 1011 bp (Figure 48, B). All 
positive clones were sequenced and used for insert production. The purified insert was ligated 
into pCAGGS and resulting clones were analyzed by colony PCR. Consequential positive 
clones were sequenced and transfected in ReNcell VM cells. The expression of N-terminally 
HA-tagged hHES1 was tested via western blot analysis. Therefore, transfected ReNcell VM 
cells were proliferated for 24 h after transfection and then differentiated for 24 h. Western blot 
analysis revealed no specific band neither by HA antibody nor by HES1 antibody (Figure 48, 
D). 
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Figure 48: Generation of pCAGGS-HA-hHES1. A: Product of HA-hHES1 amplification (M=DNA ladder). 
B: Digestion of pGEM-T easy-HA-hHES1 with XhoI and BstXI; expected fragments were 3000 bp and 1011 bp. 
C: Plasmid map of pCAGGS-HA-hHES1. D: Western blot of pCAGGS-HA-hHES1 transfected ReNcell VM 
cells after 24 h of differentiation detected by HA antibody, pCAGGS-GFP transfected cells were used as control. 
 
7.4.2 Generation of pCAGGS-HA-hHES5 
To amplify hHES5 the plasmid pCMV6-XL4-HES5 (origene) was used as a template, 
together with the forward primer which includes the XhoI restriction site in combination with 
a HA-Tag and the reverse primer which includes a BstXI restriction site. After amplification 
of HA-hHES5 (Figure 49, A) the insert was purified and ligated into pGEM-T easy (Promega) 
for subsequent blue/white screening and selection. Positive clones were analyzed by digestion 
with BstXI and XhoI, expected fragments were ca. 3000 bp and 590 bp (Figure 49, B). All 
positive clones were sequenced and used for insert production. The purified insert was ligated 
into pCAGGS and resulting clones were analyzed by colony PCR. Consequential positive 
clones were sequenced and transfected in ReNcell VM cells. The expression of N-terminally 
HA-tagged hHES1 was tested via western blot analysis. Therefore, transfected ReNcell VM 
cells were proliferated for 24 h after transfection and then differentiated for 24 h. Western blot 
analysis revealed a very weak band at 20 kDa (Figure 49, D), which was consistent with the 
pCAGGS-hHES5 vector. 
 
Appendix  IV 
 
 
 
Figure 49: Generation of pCAGGS-HA-hHES5. A: Product of HA-hHES5 amplification (M=DNA ladder). 
B: Digestion of pGEM Teasy-HA-hHES5 with XhoI and BstXI; expected fragments were 3000 bp and 590 bp. 
C: Plasmid map of pCAGGS-HA-hHES5. D: Western blot of pCAGGS-HA-hHES5 transfected ReNcell VM 
cells after 24 h of differentiation, pCAGGS-GFP transfected cells were used as control. 
 
7.5 Treatment of ReNcell VM cells with Dkk-1 
 
Figure 50: Analysis of Wnt-3a and Dkk-1 treated ReNcell VM cells Flow cytometric data showing 
percentages of Wnt-3a and Dkk-1 treated cells positive for HuC/D and Tuj1 (A) and GFAP and S100β (B) 
differentiated for 3 days in the presence of Wnt-3a+Dkk-1 (Dkk-1) or Wnt-3a alone as control. Data are 
presented as means ± SEM from two independent experiments.  
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